
OVERVIEW

OVERVIEW

HIGHLIGHTS

- Lung and Bronchus Cancer was the leading type of cancer for incidence, inpatient hospital discharges and mortality in Nevada from 1997 to 2001. This type of cancer accounted for 18.0% of the total cancer incidence, 14.9% of all cancer inpatient hospital discharges, and 32.0% of cancer mortality during this period.
- Thyroid Gland Cancer had by far the highest comparison ratio of incidence to mortality age-adjusted rates of any type of cancer in Nevada from 1997 to 2001, with a ratio of 20.54. This means that for every 100 deaths from Thyroid Gland Cancer there would be 2,054 cases. The second leading type was Uterine Cancer with a ratio of 5.98.
- Pancreatic Cancer had the lowest comparison ratio of incidence to mortality age-adjusted rates of any type of cancer in Nevada, with a ratio of 1.10 during this period. This means that for every 100 deaths from Pancreatic Cancer there were 110 cases. The second lowest leading type of cancer, Liver and Intrahepatic Bile Ducts, had a ratio of 1.20.

Figure 1. Top Ten Leading Types of Cancer by Percentage of Total Incidence, Discharges and Mortality, Nevada Residents, 1997-2001



Note: "N/A" indicates that this type of Cancer was not in the Top Ten for the respective data source.

Figure 2. Highest Incidence to Mortality Age-Adjusted Rate Ratios by Type of Cancer, Nevada Residents, 1997-2001




Figure 3. Lowest Incidence to Mortality Age-Adjusted Rate Ratios by Type of Cancer, Nevada Residents, 1997-2001




Table 1. Nevada Incidence, Inpatient Hospital Discharges and Mortality by Type of Cancer, Nevada, 1997-2001

Time of Comme	Incide	nce	Inpatient Dis	scharges	Morta	lity
Type of Cancer	Number	Rate*	Number	Rate*	Number	Rate*
Total	40,863	453.43	33,235	364.78	17,459	204.62
Lip, Oral Cavity and Pharynx	994	10.62	526	5.55	225	2.53
Lip	49	0.53	8		1	
Base of Tongue	140	1.44	79	0.81	3	
Other & Unspecified Parts of Tongue	154	1.62	97	1.03	60	0.64
Parotid Gland	69	0.77	47	0.50	13	0.15
Other & Unspecified Major Salivary glands	29	0.32	9		3	
Floor of Mouth	85	0.93	59	0.60	4	
Gum	21	0.23	27	0.30	3	
Palate	39	0.41	12	0.13	4	
Other & Unspecified Parts of Mouth	52	0.58	27	0.29	25	0.29
Nasopharynx	50	0.54	23	0.24	24	0.26
Tonsil	125	1.31	46	0.48	15	0.16
Oropharynx	44	0.47	23	0.23	8	
Pyriform Sinus	46	0.49	20	0.21	0	
Hypopharynx	33	0.35	25	0.28	3	
Other & Unspecified Oral (Buccal) Cavity & Pharynx	58 7.257	0.65	24	0.26	59	0.68
Digestive System	7,357 481	84.57 5.30	6,591 297	75.45 3.23	4,003 384	47.36 4.23
Esophagus Stomach	565	6.67	583	5.23 6.64	325	4.23 3.94
	106				28	
Small Intestine Colon (excluding Rectum)		1.17 37.79	135	1.48 33.22		0.32 19.53
Cecum Cecum	3,213 672	8.05	2,825 548	6.66	1,603 6	19.55
Appendix	35	0.39	25	0.00	2	
Ascending Colon	424	5.09	543	6.44	3	
Hepatic Flexure	109	1.28	99	1.21	0	
Transverse Colon	245	2.88	250	2.95	1	
Splenic Flexure	91	1.03	101	1.18	0	
Descending Colon	147	1.63	155	1.73	0	
Sigmoid Colon	917	10.35	793	9.14	11	0.12
Large Intestine, NOS	573	7.09	311	3.63	1,580	19.23
Rectum	770	8.62	662	7.52	200	2.31
Rectosigmoid Junction	421	4.68	576	6.41	64	0.77
Anus, Anal Canal and Anorectum	126	1.34	133	1.47	24	0.27
Liver	442	4.87	308	3.28	351	4.03
Intrahepatic Bile Ducts	73	0.85	39	0.45	64	0.74
Gallbladder	61	0.74	38	0.47	43	0.53
Other & Unspecified Biliary Tract	100	1.20	145	1.73	34	0.42
Pancreas	951	10.84	741	8.36	845	9.82
Retroperitoneum	32	0.35	53	0.57	6	
Peritoneum, Omentum and Mesentery	3		52	0.56	7	
Other Digestive Organs	13	0.14	4		25	0.31
Respiratory System	7,758	86.35	5,337	58.35	5,729	65.24
Nasal Cavity and Middle Ear	31	0.36	11	0.12	0	
Accessory Sinuses	23	0.24	17	0.18	11	0.12
Larynx	348	3.78	203	2.18	124	1.41
Lung and Bronchus	7,336	81.77	4,965	54.28	5,582	63.56
Pleura	3		66	0.78	4	
Trachea	4		18	0.19	1	
Mediastinum and Other Respiratory Organs	13	0.13	57	0.62	7	
Bones, Joints and Articular Cartilage	90	0.95	116	1.23	37	0.44
Bones, Joints & Articular Cartilage of Limbs	43	0.46	48	0.51	1	
Bones, Joints & Articular Cartilage of Other & Unspec Sites	47	0.49	68	0.71	36	0.43
Soft Tissue (Including Heart)	215	2.32	125	1.38	121	1.34
Heart	1		2		8	
Peripheral Nerves & Autonomic Nervous System	8		0		3	
Connective, Subcutaneous & Other Soft Tissues	206	2.23	123	1.36	110	1.23

^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 1. Nevada Incidence, Inpatient Hospital Discharges and Mortality by Type of Cancer, Nevada, 1997-2001 (Continued)

- /-	Incide	nce	Inpatient Dis	scharges	Morta	lity
Type of Cancer	Number	Rate*	Number	Rate*	Number	Rate*
Total	40,863	453.43	33,235	364.78	17,459	204.62
Skin (Excluding Basal And Squamous)	1,189	12.82	240	2.72	345	3.89
Melanomas Of The Skin	1,083	11.59	83	0.91	264	2.92
Other Non-Epithelial Skin	106	1.23	157	1.81	81	0.98
Breast	6,493	70.45	2,608	28.45	1,195	14.02
Female Genital System*	2,250	47.38	2,349	49.24	690	15.03
Cervix Uteri*	497	10.39	646	13.39	140	2.99
Corpus Uteri*	808	16.94	801	16.73	59	1.30
Uterus, NOS*	44	0.96	27	0.58	75	1.70
Ovary*	737	15.54	669	14.04	376	8.16
Vagina*	39	0.83	53	1.13	12	0.25
Vulva*	112	2.45	117	2.63	15	0.35
Placenta*	1		1		1	
Other Female Genital Organs*	12	0.24	35	0.71	12	0.26
Male Genital System*	5,605	131.04	2,605	57.52	943	29.68
Prostate*	5,337	125.66	2,536	56.03	922	29.21
Testis*	237	4.63	51	0.98	17	0.34
Penis*	19	0.48	15	0.45	4	
Other Male Genital Organs*	12	0.40	3		0	
Urinary System	3,218	36.33	1,995	22.37	748	9.06
Urinary Bladder	2,068	23.86	1,022	11.93	401	5.09
Kidney	1,014	10.96	819	8.73	322	3.69
Renal Pelvis	76	0.84	86	0.73	5	3.09
Ureter	38		49		12	
		0.44		0.54		0.14
Other Urinary Organs	22 50	0.23 0.54	19 4	0.20	8 6	
Eye and Orbit						
Brain and Other Central Nervous System	580	6.21	762	8.05	338	3.71
Brain	540	5.78	706	7.47	335	3.68
Meninges	20	0.21	37	0.39	0	
Spinal Cord, Cranial Nerves, & Other Parts of CNS	20	0.22	19	0.19	3	
Endocrine System	757	7.77	1,032	10.56	53	0.61
Thyroid Gland	696	7.12	985	10.06	29	0.35
Adrenal Gland	30	0.33	21	0.22	15	0.17
Other Endocrine (Including Thymus)	31	0.32	26	0.28	9	
Hodgkin's Lymphoma	214	2.20	116	1.19	38	0.40
Non-Hodgkin's Lymphoma	1,316	14.65	988	11.01	599	7.08
Multiple Myeloma	372	4.20	321	3.49	261	3.02
Leukemia	1,059	12.05	1,080	11.77	614	7.39
Lymphocytic	451	5.03	440	4.72	164	2.06
Acute Lymphocytic	141	1.44	286	2.92	32	0.34
Chronic Lymphocytic	278	3.23	150	1.76	120	1.55
Other Lymphocytic	32	0.36	4		12	0.17
Myeloid and Monocytic	478	5.40	573	6.30	249	2.89
Acute Myeloid	330	3.66	458	5.00	180	2.07
Acute Monocytic	17	0.19	9		0	
Chronic Myeloid	108	1.27	103	1.17	53	0.63
Other Myeloid/Monocytic	23	0.28	3		16	0.19
Other	130	1.61	67	0.75	201	2.43
Other Acute	49	0.61	47	0.54	88	1.02
Aleukemic, Subleukemic and NOS	81	1.01	20	0.21	113	1.41
Mesothelioma	91	1.08	0		46	0.56
Kaposi Sarcoma	54	0.58	2		0	
Other, III-Defined and Unspecified Sites	1,201	13.98	6,438	70.48	1,468	17.57

^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" is used for rates calculated on numbers less than ten. Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 2. Leading Types of Cancer for Nevada Incidence, Inpatient Hospital Discharges and Mortality, Nevada Residents, 1997-2001

Type of Cancer	Incide	ence	Hos Admis		Mort	tality
,	Number	Percent	Number	Percent	Number	Percent
Lung and Bronchus	7,336	18.0%	4,965	14.9%	5,582	32.0%
Breast	6,493	15.9%	4,196	12.6%	1,891	10.8%
Prostate	5,337	13.1%	2,608	7.8%	1,195	6.8%
Colorectal	4,530	11.1%	2,536	7.6%	922	5.3%
Urinary Bladder	2,068	5.1%	1,080	3.2%	845	4.8%
Non-Hodgkin's Lymphoma	1,316	3.2%	1,022	3.1%	614	3.5%
Kidney and Renal Pelvis	1,090	2.7%	988	3.0%	599	3.4%
Skin	1,083	2.7%	985	3.0%	415	2.4%
Leukemia	1,059	2.6%	905	2.7%	401	2.3%
Lip, Oral Cavity and Pharynx	994	2.4%	828	2.5%	384	2.2%
Pancreas	951	2.3%	762	2.3%	376	2.2%
Corpus Uteri & Uterus NOS	852	2.1%	741	2.2%	338	1.9%
Ovary	737	1.8%	669	2.0%	327	1.9%
Thyroid Gland	696	1.7%	646	1.9%	325	1.9%
Brain and Other Central Nervous System	580	1.4%	583	1.8%	264	1.5%
Stomach	565	1.4%	526	1.6%	261	1.5%
Liver and Intrahepatic Bile Ducts	515	1.3%	347	1.0%	225	1.3%
Cervix Uteri	497	1.2%	321	1.0%	140	0.8%
Esophagus	481	1.2%	297	0.9%	134	0.8%
Multiple Myeloma	372	0.9%	203	0.6%	124	0.7%
Larynx	348	0.9%	116	0.3%	38	0.2%
Hodgkin's Lymphoma	214	0.5%	83	0.2%	29	0.2%
All Other Sites	2,749	6.7%	7,828	23.6%	2,030	11.6%
Total	40,863	100.0%	33,235	100.0%	17,459	100.0%

Note: Caution should be used when comparing inpatient hospital discharge data to other data sources, since it is occurrence-based data. Please see Technical Notes for more information.

Table 3. Top Ten Types of Cancer by Gender, Incidence, Hospital Discharges, and Mortality, Nevada Residents, 1997-2001

				To	otal				
Ranking	Incidenc	е		Hospital Admissions		Mortality			
	Type	Number	Percent	Type	Number	Percent	Type	Number	Percent
1	Lung and Bronchus	7,336	18.0%	Lung and Bronchus	4,965	14.9%	Lung and Bronchus	5,582	32.0%
2	Breast	6,493	15.9%	Colorectal	4,196	12.6%	Colorectal	1,891	10.8%
3	Prostate	5,337	13.1%	Breast	2,608	7.8%	Breast	1,195	6.8%
4	Colorectal	4,530	11.1%	Prostate	2,536	7.6%	Prostate	922	5.3%
5	Urinary Bladder	2,068	5.1%	Leukemia	1,080	3.2%	Pancreas	845	4.8%
6	Non-Hodgkin's Lymphoma	1,316	3.2%	Urinary Bladder	1,022	3.1%	Leukemia	614	3.5%
7	Kidney and Renal Pelvis	1,090	2.7%	Non-Hodgkin's Lymphoma	988	3.0%	Non-Hodgkin's Lymphoma	599	3.4%
8	Skin	1,083	2.7%	Thyroid Gland	985	3.0%	Liver and Intrahepatic Bile Ducts	415	2.4%
9	Leukemia	1,059	2.6%	Kidney and Renal Pelvis	905	2.7%	Urinary Bladder	401	2.3%
10	Lip, Oral Cavity and Pharynx	994	2.4%	Corpus Uteri & Uterus NOS	828	2.5%	Esophagus	384	2.2%
	Total of Top 10	31,306		Total of Top 10	20,113	60.5%	Total of Top 10	12,848	73.6%
-	Total	40,863	100.0%	Total	33,235	100.0%	Total	17,459	100.0%

					Male				
Ranking	Incidenc	е		Hospital A	dmissions		Mortality		
	Туре	Number	Percent	Type	Number	Percent	Type	Number	Percent
1	Prostate	5,337	25.4%	Lung and Bronchus	2,601	16.1%	Lung and Bronchus	3,125	33.0%
2	Lung and Bronchus	3,970	18.9%	Prostate	2,536	15.7%	Colorectal	1,055	11.1%
3	Colorectal	2,419	11.5%	Colorectal	2,169	13.5%	Prostate	922	9.7%
4	Urinary Bladder	1,567	7.4%	Urinary Bladde r	762	4.7%	Pancreas	419	4.4%
5	Non-Hodgkin's Lymphoma	737	3.5%	Leukemia	628	3.9%	Leukemia	368	3.9%
6	Kidney and Renal Pelvis	706	3.4%	Kidney and Renal Pelvis	586	3.6%	Non-Hodgkin's Lymphoma	356	3.8%
7	Lip, Oral Cavity and Pharynx	695	3.3%	Non-Hodgkin's Lymphoma	550	3.4%	Esophagus	294	3.1%
8	Skin	634	3.0%	Brain and Other Central Nerv	ous System449	2.8%	Urinary Bladder	288	3.0%
9	Leukemia	629	3.0%	Stomach	398	2.5%	Liver and Intrahepatic Bile Ducts	272	2.9%
10	Pancreas	502	2.4%	Pancreas	390	2.4%	Kidney and Renal Pelvis	226	2.4%
							-		
	Total of Top 10	17,196	81.7%	Total of Top 10	11,069	68.6%	Total of Top 10	7,325	77.3%
-	Total	21,042	100.0%	Total	16,125	100.0%	Total	9,476	100.0%

				Fema	ale				
Ranking	Incidenc	е		Hospital Admi	ssions		Mortality		
	Туре	Number	Percent	Type	Number	Percent	Type	Number	Percent
1	Breast	6,420	32.4%	Breast	2,589	15.1%	Lung and Bronchus	2,457	30.8%
2	Lung and Bronchus	3,366	17.0%	Lung and Bronchus	2,364	13.8%	Breast	1,182	14.8%
3	Colorectal	2,111	10.7%	Colorectal	2,027	11.8%	Colorectal	836	10.5%
4	Corpus Uteri & Uterus NOS	852	4.3%	Corpus Uteri & Uterus NOS	828	4.8%	Pancreas	426	5.3%
5	Ovary	737	3.7%	Thyroid Gland	769	4.5%	Ovary	376	4.7%
6	Non-Hodgkin's Lymphoma	579	2.9%	Ovary	669	3.9%	Leukemia	246	3.1%
7	Thyroid Gland	539	2.7%	Cervix Uteri	646	3.8%	Non-Hodgkin's Lymphoma	243	3.0%
8	Urinary Bladder	501	2.5%	Leukemia	452	2.6%	Liver and Intrahepatic Bile Ducts	143	1.8%
9	Cervix Uteri	497	2.5%	Non-Hodgkin's Lymphoma	438	2.6%	Cervix Uteri	140	1.8%
10	Pancreas	449	2.3%	Pancreas	351	2.1%	Corpus Uteri & Uterus NOS	134	1.7%
	Total of Top 10	16,051	81.0%	Total of Top 10	11,133	65.1%	Total of Top 10	6,183	77.5%
-	Total	19,821	100.0%	Total	17,110	100.0%	Total	7,983	100.0%

Note: Those of other/unknown gender are not listed separately, but are included in the total.

Table 4. Incidence to Mortality Age-Adjusted Rate Ratios for the Leading Types of Cancer, Nevada Residents, 1997-2001

Turns of Operator		Incidence	e		Ratio		
Type of Cancer	Number	Rate*	95% C.I.	Number	Rate*	95% C.I.	Katio
Lung and Bronchus	7,336	81.8	(79.9-83.7)	5,582	63.6	(61.9-65.3)	1.29
Breast*	6,420	135.2	(131.9-138.6)	1,182	25.9	(24.4-27.4)	5.22
Prostate*	5,337	125.7	(122.1-129.4)	922	29.2	(27.2-31.4)	4.30
Colorectal	4,530	52.4	(50.9-54.0)	1,891	22.9	(21.8-24.0)	2.29
Urinary Bladder	2,068	23.9	(22.8-24.9)	401	5.1	(4.6-5.6)	4.69
Non-Hodgkin's Lymphoma	1,316	14.7	(13.9-15.5)	599	7.1	(6.5-7.7)	2.07
Kidney and Renal Pelvis	1,090	11.8	(11.1-12.5)	327	3.7	(3.3-4.2)	3.15
Leukemia	1,059	12.0	(11.3-12.8)	614	7.4	(6.8-8.0)	1.63
Lip, Oral Cavity and Pharynx	994	10.6	(10.0-11.3)	225	2.5	(2.2-2.9)	4.21
Pancreas	951	10.8	(10.1-11.6)	845	9.8	(9.1-10.5)	1.10
Skin	1,083	11.6	(10.9-12.3)	264	2.9	(2.6-3.3)	3.98
Corpus Uteri & Uterus NOS*	852	17.9	(16.7-19.2)	134	3.0	(2.5-3.6)	5.98
Ovary*	737	15.5	(14.4-16.7)	376	8.2	(7.3-9.0)	1.90
Thyroid Gland	696	7.1	(6.6-7.7)	29	0.3	(0.2-0.5)	20.54
Brain and Other Central Nervous System	580	6.2	(5.7-6.8)	338	3.7	(3.3-4.2)	1.67
Stomach	565	6.7	(6.1-7.3)	325	3.9	(3.5-4.4)	1.69
Liver and Intrahepatic Bile Ducts	515	5.7	(5.2-6.2)	415	4.8	(4.3-5.3)	1.20
Cervix Uteri*	497	10.4	(9.5-11.4)	140	3.0	(2.5-3.5)	3.48
Esophagus	481	5.3	(4.8-5.8)	384	4.2	(3.8-4.7)	1.25
Larynx	348	3.8	(3.4-4.2)	124	1.4	(1.2-1.7)	2.68
Multiple Myeloma	372	4.2	(3.8-4.7)	261	3.0	(2.7-3.4)	1.39
Hodgkin's Lymphoma	214	2.2	(1.9-2.5)	38	0.4	(0.3-0.6)	5.44
All Other Sites	2,749	31.0	(29.8-32.2)	2,030	24.1	(23.1-25.2)	1.29
Total	40,863	453.4	(448.9-457.9)	17,459	204.6	(201.5-207.8)	2.22


 $[\]ast$ Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

INCIDENCE

HIGHLIGHTS

- Lung and Bronchus Cancer was the leading type of cancer in Nevada from 1997 to 2001. This type of cancer accounted for 18.0% of all resident cancer cases during this period. The second leading type, Breast Cancer, accounted for 15.9% of all cancer incidence.
- ➤ When compared to National (1997-2001) incidence, Nevada had a much higher incidence of Lung and Bronchus Cancer, 18.0% vs 12.9%, and a considerably lower incidence of Breast Cancer: 15.9% vs 18.2% during the 1997-2001 period.
- ➤ While Blacks had the highest ratio of the remaining racial/ethnic groups when compared to the age-adjusted cancer incidence rates for Whites, their ratio was just 0.94. This means that for every 100 White cancer cases Blacks would be expected to have 94 cases. Asians, Hispanics and Native Americans had comparison ratios of 0.49, 0.46 and 0.40, respectively, for Nevada from 1997 to 2001.
- ➤ Liver and Inrahepatic Bile Ducts had the highest age-adjusted incidence comparison ratio for Blacks when compared to Whites in Nevada from 1997 to 2001 with a comparison ratio of 1.68. Meaning for every 100 White Liver and Inrahepatic Bile Ducts cases Blacks would be expected to have 168 cases. This cancer type also had the highest comparison ratio for Asians with a 2.03 ratio. Stomach cancer had the highest comparison incidence ratio for Hispanics with 0.93. Multiple Myeloma had the highest comparison ratio for Native Americans when compared to Whites with a ratio of 1.90.
- ➤ Hodgkin's Lymphoma had the lowest median age at time of diagnosis for Nevada residents from 1997 to 2001 at 39 years. The median age for females diagnosed with Hodgkin's Lymphoma was 37 years, while for males it was 43 years.
- ➤ Stomach and Urinary Bladder Cancers had the highest median age at time of diagnosis for Nevada residents during the 1997 to 2001 period at 71 years. The median age for females diagnosed with Stomach Cancer was 72 years, while for males it was 70 years, which was equivalent to the median age at diagnosis of Urinary Bladder Cancer for males during this period.

Figure 4. Top Ten Leading Cancers as a Percentage of Total Cases, Nevada (1997-2001) and SEER-11 (1997-2001)



Note: "N/A" indicates that this type of Cancer was not in the Top Ten for the SEER region.

Figure 5. Comparison of Age-Adjusted (2001) Incidence Rates of Blacks compared to Whites, Nevada Residents, 1997-2001





Figure 6. Comparison of Age-Adjusted (2001) Incidence Rates of Native Americans compared to Whites, Nevada Residents, 1997-2001



Note: "N/A" indicates that a comparison ratio could not be calculated.

Figure 7. Comparison of Age-Adjusted (2001) Incidence Rates of Asians compared to Whites, Nevada Residents, 1997-2001




Figure 8. Comparison of Age-Adjusted (2001) Incidence Rates of Hispanics compared to Whites, Nevada Residents, 1997-2001




Table 5. Nevada Incidence by Type of Cancer, Nevada (1997-2001) and SEER-11 (1997-2001)

	Incid	dence (1997	-2001)	SE	ER-11 (1997-2	2001)
Type of Cancer	Number	Rate*	95% C.I.	Number	Rate*	95% C.I.
Total	40,863	453.43	(448.9-457.9)	815,121	483.42	(482.4-484.5)
Lip, Oral Cavity and Pharynx	994	10.62	(10.0-11.3)	18,648	11.04	(10.9-11.2)
Lip	49	0.53	(0.4-0.7)	1,789	1.06	(1.0-1.1)
Base of Tongue	140	1.44	(1.2-1.7)	1,855	1.11	(1.1-1.2)
Other & Unspecified Parts of Tongue	154	1.62	(1.4-1.9)	2,400	1.42	(1.4-1.5)
Parotid Gland	69	0.77	(0.6-1.0)	1,594	0.93	(0.9-1.0)
Other & Unspecified Major Salivary glands	29	0.32	(0.2-0.5)	441	0.26	(0.2-0.3)
Floor of Mouth	85	0.93	(0.7-1.2)	1,513	0.91	(0.9-1.0)
Gum	21	0.23	(0.1-0.4)	736	0.44	(0.4-0.5)
Palate	39	0.41	(0.3-0.6)	1,127	0.66	(0.6-0.7)
Other & Unspecified Parts of Mouth	52	0.58	(0.4-0.8)	1,207	0.72	(0.7-0.8)
Nasopharynx	50	0.54	(0.4-0.7)	1,331	0.77	(0.7-0.8)
Tonsil	125	1.31	(1.1-1.6)	2,064	1.23	(1.2-1.3)
Oropharynx	44	0.47	(0.3-0.6)	529	0.32	(0.3-0.3)
Pyriform Sinus	46	0.49	(0.4-0.7)	978	0.59	(0.5-0.6)
Hypopharynx	33	0.35	(0.2-0.5)	552	0.33	(0.3-0.4)
Other & Unspecified Oral (Buccal) Cavity & Pharynx	58 7.057	0.65	(0.5-0.9)	532	0.32	(0.3-0.3)
Digestive System	7,357	84.57	(82.6-86.6)	151,274	90.82	(90.4-91.3)
Esophagus	481	5.30	(4.8-5.8)	7,483	4.49	(4.4-4.6)
Stomach	565	6.67	(6.1-7.3)	15,187	9.10	(9.0-9.2)
Small Intestine	106	1.17	(1.0-1.4)	2,753	1.64	(1.6-1.7)
Colon (excluding Rectum)	3,213	37.79	(36.5-39.2)	64,345	38.75	(38.5-39.1)
Cecum Appendix	672 35	8.05 0.39	(7.4-8.7)	14,990 714	9.05 0.42	(8.9-9.2)
			(0.3-0.6)			(0.4-0.4)
Ascending Colon	424 109	5.09 1.28	(4.6-5.6)	9,862 3,655	5.95 2.21	(5.8-6.1)
Hepatic Flexure		2.88	(1.0-1.6)		3.60	(2.1-2.3)
Transverse Colon Splenic Flexure	245 91	1.03	(2.5-3.3) (0.8-1.3)	5,972 2,483	1.49	(3.5-3.7) (1.4-1.6)
Descending Colon	147	1.63	(1.4-1.9)	2,403 3,907	2.34	(2.3-2.4)
Sigmoid Colon	917	10.35	(9.7-11.1)	19,474	11.70	(11.5-11.9)
Large Intestine, NOS	573	7.09	(6.5-7.7)	3,288	1.99	(1.9-2.1)
Rectum	770	8.62	(8.0-9.3)	16,598	9.93	(9.8-10.1)
Rectosigmoid Junction	421	4.68	(4.2-5.2)	8,180	4.91	(4.8-5.0)
Anus, Anal Canal and Anorectum	126	1.34	(1.1-1.6)	2,189	1.29	(1.2-1.3)
Liver	442	4.87	(4.4-5.4)	8,044	4.79	(4.7-4.9)
Intrahepatic Bile Ducts	73	0.85	(0.7-1.1)	1,460	0.88	(0.8-0.9)
Gallbladder	61	0.74	(0.6-1.0)	2,064	1.24	(1.2-1.3)
Other & Unspecified Biliary Tract	100	1.20	(1.0-1.5)	2,372	1.43	(1.4-1.5)
Pancreas	951	10.84	(10.1-11.6)	18,152	10.93	(10.8-11.1)
Retroperitoneum	32	0.35	(0.2-0.5)	737	0.43	(0.4-0.5)
Peritoneum, Omentum and Mesentery	3			1,033	0.61	(0.6-0.7)
Other Digestive Organs	13	0.14	(0.1-0.3)	677	0.41	(0.4-0.4)
Respiratory System	7,758	86.35	(84.4-88.3)	114,569	68.69	(68.3-69.1)
Nasal Cavity and Middle Ear	31	0.36	(0.2-0.5)	563	0.33	(0.3-0.4)
Accessory Sinuses	23	0.24	(0.2-0.4)	621	0.37	(0.3-0.4)
Larynx	348	3.78	(3.4-4.2)	6,718	4.02	(3.9-4.1)
Lung and Bronchus	7,336	81.77	(79.9-83.7)	104,761	62.85	(62.5-63.2)
Pleura	3			1,529	0.92	(0.9-1.0)
Trachea	4			117	0.07	(0.1-0.1)
Mediastinum and Other Respiratory Organs	13	0.13	(0.1-0.2)	260	0.14	(0.1-0.2)
Bones, Joints and Articular Cartilage	90	0.95	(0.8-1.2)	1,618	0.90	(0.9-0.9)
Bones, Joints & Articular Cartilage of Limbs	43	0.46	(0.3-0.6)	866	0.48	(0.4-0.5)
Bones, Joints & Articular Cartilage of Other & Unspec Sites	47	0.49	(0.4-0.7)	752	0.42	(0.4-0.5)
Soft Tissue (Including Heart)	215	2.32	(2.0-2.7)	4,924	2.81	(2.7-2.9)
Heart	1		\	48	0.03	(0.0-0.0)
Peripheral Nerves & Autonomic Nervous System	8			281	0.15	(0.1-0.2)
Connective, Subcutaneous & Other Soft Tissues	206	2.23	(1.9-2.6)	4,595	2.63	(2.6-2.7)
						· · · · · · · · · · · · · · · · · · ·

^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Table 5. Nevada Incidence by Type of Cancer, Nevada (1997-2001) and SEER-11 (1997-2001) (Continued)

Name	T		Incidence		SEI	ER-11 (1995-	1999)
Skin (Excluding Basal And Squamous)	Type of Cancer	Number	Rate*	95% C.I.	Number	Rate*	95% C.I.
Melanomas OTThe Skin 1,083 11,093 11,093 12,093 12,093 16,131 (16.11-6.5) Cherk OTHer Dithelial Skin 106 1.23 (10.11-5.5) 5,785 3.22 (2.13-3.3) Breast* 2,260 47,38 (46.4-48.4) 5,000 55,03 (54.5-55.5) 6,262 (54.5-6.2) Female Genital System* 2,260 47,38 (46.4-48.4) 8,000 55,03 (54.5-55.5) 6,000	Total	40,863	453.4	(448.9-457.9)	815,121	483.42	(482.4-484.5)
Melanomas OT The Skin 1,083 11,083 11,093 11,093 12,093 12,093 16,31 (16,1-16,5) Cherk OTher Deliberial Skin 106 1,22 (13,1-9,136,5) 13,095 (13,1-9,136,5) 13,095 (13,1-9,136,5) 14,7688 16,28 (13,1-9,136,5) 14,7688 14,7688 16,28 (14,1-6,16,5) 14,7688 14,7689 14,7688 14,7	Ckin (Evoluting Boool And Squamous)	1 100	10.00	(12.1.12.6)	24.077	10.52	(10.2.10.7)
Deba				,			,
Breast* 6,420 185.20 (131)-188.60 147,688 161,28 (165,545) (56,555) (54,555) (54,555) (54,555) (56,555) (54,555) (56,555) (54,555) (56,555) (54,555) (56,555) (56,555) (56,555) (56,555) (56,555) (56,555) (56,555) (56,670) (56,700) <th< td=""><td></td><td></td><td></td><td>,</td><td></td><td></td><td>,</td></th<>				,			,
Female Cenital System* 2,250 47.38 (45.44.94) 50.00 55.03 (54.55.5) Corpus Uten* 480 16.94 (15.81.82) 22.211 24.26 (23.924.6) Uterus, NOS* 44 0.96 (0.71.3) 16.81 (14.16.7) 15.611 16.84 (16.61.71) Valga* 39 0.83 (0.61.1) 15.611 16.84 (16.61.71) Valga* 39 0.83 (0.61.1) 15.611 16.67 0.0 (0.61.31) Placenta* 11 2.45 (20.30) 2.117 2.22 (21.23) Placenta* 1 0.24 (0.10.4) 594 (0.64 (0.60.77) Male Genital System* 5,05 13.104 (127.41.814) 115.22 (21.23) (0.10.8) (0.54) (0.64 (0.66.77) Male Genital System* 5,337 125.66 (127.12.94 119.272 165.54 (164.61.65.5) (0.74.8) (0.74.1) (0.70.8) (0.77.9) (0.77.8) (0.77.8)	• • • • • • • • • • • • • • • • • • •			, ,			
Cernix Uterir				,			
Corpus Uner* 488 (16,94) (15,18-18.2) 22,211 24,26 (23,9-46) Uterus, NOS* 44 40,96 (0,7-13) 15,54 (14,4-16.7) 15,611 16,84 (16,6-17.1) Valgna* 39 0,83 (0,6-11) 15,611 16,67 0,70 (0,6-0.2) Valya* 112 2,45 (2,0-3.0) 2,117 2,22 (2,1-2.3) Placanta* 1 - - 66 0,00 (0,1-0.4) 0,00 (0,1-0.4) 0,00 (0,1-0.4) 0,00 (0,1-0.4) 0,00 (0,1-0.4) 0,00 (0,1-0.2) 0,00 (0,1-0.2) 0,00 (0,1-0.2) 0,00 (0,1-0.2) 0,00 (0,1-0.2) 0,00 (0,1-0.2) 0,00 (0,1-0.2) 0,00 (0,1-0.2) 0,00 (0,1-0.2) 0,00 (0,1-0.2) 0,00 (0,1-0.2) 0,00 (0,1-0.2) 0,00 (0,1-0.2) 0,00 (0,1-0.2) 0,00 (0,1-0.2) 0,00 (0,1-0.2) 0,00 (0,1-0.2) 0,	· · · · · · · · · · · · · · · · · · ·			,			
Uterius, NOS* 44 0,96 (0,7-13) 423 0,44 (0,4-0.5) Ovary* 737 15.54 (14.4-16.1) 15.611 16.84 (16.6-17.1) Vagina* 39 0.83 0.06-1.1 0.675 0.70 (0,6-0.8) Vulva* 112 2.45 (203) 0.2117 0.22 (21.23) Placenta* 1 0.86 0.09 (0,1-0.1) Placenta* 1 0.70 0.60-0.8 Placenta* 1 0.70 0.60-0.8 Placenta* 1 0.70 0.10-1.0 0.594 0.00-0.0 Male Genital Organs* 15.605 131.04 (17.4-134.8) 125.02 171.72 (170.8-172.7) Placenta* 19 0.48 0.04-0.8 0.09-0.8 0.09-0.0 Placenta* 19 0.48 0.04-0.8 0.09-0.8 0.09-0.0 Placenta* 19 0.48 0.04-0.8 0.09-0.8 0.09-0.0 Placenta* 19 0.48 0.04-0.8 0.09-0.0 Other Male Genital Organs* 12 0.27 0.10-0.8 0.529 0.74 0.70-0.8 Other Male Genital Organs* 12 0.27 0.10-0.8 0.529 0.74 0.70-0.8 Utriany System 3,218 0.28 0.28-24 0.28-24 0.29 0.30-0.4 Utriany Bladder 2,068 23.86 0.28-24 0.32-24 0.09-1.0 Utriany Bladder 2,068 0.38 0.07-1.1 15.55 0.94 0.9-1.0 Utreta* 38 0.44 0.07-1.1 15.55 0.94 0.9-1.0 Utreta* 38 0.44 0.07-1.1 15.55 0.94 0.9-1.0 Utreta* 38 0.44 0.07-1.1 15.55 0.95 0.50-0.0 Eye and Orbit 0.70 0.70 0.70 0.70 0.70 Brain and Other Central Nervous System 550 6.21 0.75 0.75 0.50 0.00 Eye and Orbit 0.70 0.70 0.70 0.70 0.70 0.70 0.70 Endocrine System 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 Endocrine System 0.70 0.							
Ovary's Valina's Valina'	·			,			,
Vagina* 39 0.83 0.06.1.1 657 0.70 (0.60-0.8) Vulva* 112 2.45 50.20.3 2.117 2.22 (2.1-2.3) Placenta* 1 68 0.09 (0.1-0.1) Maie Genital System* 5.605 131.04 (17.4-134.8) 125.029 171.72 (164.6-165.5) Penis* 5.33 71.566 (122.1-124.8) 19.272 (164.6-165.5)				, ,			
Vulvar 1112 2.45 (20-30) 2.117 2.22 (21-23) Placental 1 1 0.0 (0.10-4) 564 0.06 (0.6-0.7) Male Genital Organs* 12 0.24 (0.10-4) 1554 (170-8-172-7) Prostate* 5,337 125.86 (122-1-120-4) 119,272 165.54 (164-6-165) Tesits* 237 4.63 (121-120-4) 119,272 165.54 (164-6-165) (167-60-100-100-100-100-100-100-100-100-100-	·			,			
Dither Female Genital Organs* 12 0.24 (0.10.4) 554 (0.60.7) Male Genital System* 5.655 13.04 (171.41.48) 125.020 171.72 (170.8-172.71) Prostate* 5.337 126.66 (122.1-120.4) 119.272 185.54 (164.6-166.5) Tesiis* 7.538 1.00.60 1.00.70 1.00.				,			, ,
Other Female Genital Organs* 12 0.24 (0.10.4) 554 0.06.07 Male Genital System* 5.655 5.134 127.14.148 125.02 171.72 (170.8-172.72) Prostate* 5.337 126.66 (122.1-12.94) 119.272 165.54 (164.6-16.5) Testis* 237 4.63 (14.1.3) 4.96 5.03 (16.6-6.5) Penis* 19 0.48 (0.3-0.8) 5.29 0.74 (0.7-0.8) Other Male Genital Organs* 19 0.48 (0.3-0.8) 5.29 0.74 (0.7-0.8) Urinary System 2.08 23.86 (22.8-24.9) 33.24 20.01 (19.8-20.2) Kidney 76 0.84 (0.7-1.1) 1.65.22 9.55 (9.7-10.0) Penal Delvis 76 0.84 (0.7-1.1) 1.558 0.94 (0.9-10.0) Urieter 360 6.21 (5.7-6.8) 11.214 6.41 (6.9-6.7) Eye and Orbit 400 400 7.7	Placenta*	1		, ,		0.09	,
Prostate* 5,337 125.66 (122.1-129.4 119.272 166.54 (164.6-166.5) Testis* 19 0.48 (0.3-0.8) 5.29 0.74 (0.7-0.8) Other Male Genital Organs* 12 0.27 (0.1-0.6) 5.29 0.74 (0.7-0.8) Other Male Genital Organs* 3,218 36.33 (35.1-37.7) 0 0.3-0.4 Other Male Genital Organs* 2,068 23.86 (22.8-24.9) 33.284 20.01 (19.8-0.22) Kidney 1,014 10.96 (10.3-11.7) 15.59 0.95 (0.3-0.4) Renal Pelvis 76 0.84 (0.7-1.1) 1.558 0.94 (0.9-1.0) Other Urinary Organs 22 0.23 (0.1-0.4) 578 0.35 (0.3-0.4) Eye and Orbit 50 0.54 (0.7-1.1) 1.558 0.94 (0.9-1.0) Frain and Other Central Nervous System 550 6.21 (5.7-6.8) 11.214 6.41 (6.3-6.5) Brain and Other Central Nervous System 550 6.21 (0.1-0.3) 190 0.11 (0.1-0.1) Spinal Cord, Cranial Nerves, & Other Parts of CNS 20 0.22 (0.1-0.3) 190 0.11 (0.1-0.1) Spinal Cord, Cranial Nerves, & Other Parts of CNS 20 0.22 (0.1-0.3) 190 0.11 (0.1-0.1) Throid Gland 696 7.12 (6.6-7.7) 11.85 6.6 (6.5-7.6.8) Adrenal Gland 30 0.33 (0.2-0.5) 6.13 0.28 (0.3-0.3) Other Endocrine (Including Thymus) 31 0.32 (0.2-0.5) 6.13 0.28 (0.3-0.3) Other Endocrine (Including Thymus) 31 4.62 0.38-4.7 9.106 5.47 (5.4-6.8) Hodgkin's Lymphoma 72 4.62 0.38-4.7 9.106 5.47 (5.4-6.8) Hodgkin's Lymphoma 72 4.62 0.38-4.7 9.106 5.47 (5.4-6.8) Hodgkin's Lymphocytic 451 0.34 0.34 0.3-0.3	Other Female Genital Organs*	12	0.24	(0.1-0.4)	594	0.64	, ,
Testis*	Male Genital System*	5,605	131.04	(127.4-134.8)	125,029	171.72	(170.8-172.7)
Penis* Other Male Genital Organs*	Prostate*	5,337	125.66	(122.1-129.4)	119,272	165.54	(164.6-166.5)
Other Male Genital Organs* 12 0.27 (0.1-0.6) 261 0.35 (0.3-0.4) Urinary System 3,218 36,33 (35,1-37,7) 0 Urinary Bladder 2,068 23,86 (22,8-24,9) 33,264 20,01 (19,8-20,2) Kidney 1,014 1,036 (10,3-11,7) 16,592 9,85 (9,7-10.0) Ureter 38 0,44 (0,3-0.6) 877 0,53 (0,5-0.6) Other Urinary Organs 22 0,23 (0,1-0.4) 578 0,35 (0,7-0.8) Brain and Other Central Nervous System 550 0,5-1 (0,1-0.4) 1578 0,79 (0,7-0.8) Brain and Other Cantial Nerves, & Other Parts of CNS 20 0,21 (0,1-0.3) 190 0,11 (0,1-0.1) Brain Aginal Cord, Canial Nerves, & Other Parts of CNS 20 0,22 (0,1-0.4) 483 0,27 (0,1-0.3) 10 0,11 (0,1-0.1) 1,1 0,1 0,1 0,1 0,1 0,1 0,1	Testis*	237	4.63	(4.1-5.3)	4,967	5.08	(4.9-5.2)
Urinary System	Penis*	19	0.48	(0.3-0.8)	529	0.74	(0.7-0.8)
Virinary Bladder	Other Male Genital Organs*	12	0.27	(0.1-0.6)	261	0.35	(0.3-0.4)
Kidney 1,014 10,96 (10,3-11.7) 16,592 9,85 (9,7-10.0) Renal Pelvis 76 0.84 (0,7-1.1) 1,558 0.94 (0,9-1.0) Ureter 38 0.44 (0,3-0.6) 877 0,53 (0,5-0.6) Other Urinary Organs 22 0,23 (0,1-0.4) 578 0,35 (0,3-0.4) Eye and Orbit 50 0,54 (0,4-0.7) 1,376 0,79 (0,7-0.8) Brain and Other Central Nervous System 580 6,21 (5,7-6.8) 11,214 6,41 (6,3-6.5) Brain 540 5,78 (5,3-6.3) 10,541 (6,0) (0,1-0.1) Spinal Cord, Cranial Nerves, & Other Parts of CNS 20 0,22 (0,1-0.3) 190 0,11 (0,1-0.1) Spinal Cord, Cranial Nerves, & Other Parts of CNS 20 0,22 (0,1-0.4) 483 0,27 (0,2-0.3) Endocrine System 757 7,77 (7,2-8.4) 13,034 7,22 (7,1-7.3) Thyroid Gland 606 7,12 (6,6-7.7) 11,885 6,58 (6,5-6.7) Adrenal Gland 30 0,33 (0,2-0.5) 533 0,28 (0,3-0.4) Hodgkin's Lymphoma 214 2,20 (1,9-2.5) 5,019 0,271 (2,6-2.8) Non-Hodgkin's Lymphoma 1,316 14,65 (1,3-9.15.5) 32,597 19,13 (18,9-19.3) Multiple Myeloma 372 4,20 (1,3-12.8) 20,646 12,06 (1,9-12.5) Acute Lymphocytic 451 5,03 (4,6-5.5) 8,924 5,18 (5,1-5.3) Acute Lymphocytic 278 3,23 (2,3-0.5) 2,96 0,18 (1,9-12.6) Granulocytic (Myeloid) 30 3,66 (3,3-4.1) 6,141 3,9 (3,5-3.7) Chronic Lymphocytic 31 2,4 3,4 4	Urinary System			(35.1-37.7)	0		
Renal Pelvis 76 0.84 0.7-1.1) 1,558 0.94 (0.9-1.0) Ureter 38 0.44 (0.3-0.6) 877 0.53 (0.5-0.6) Other Urinary Organs 22 0.23 (0.1-0.4) 578 0.35 (0.5-0.4) Eye and Orbit 50 0.54 (0.4-0.7) 1,376 0.79 (0.7-0.8) Brain and Other Central Nervous System 580 6.21 (5.7-8.8) 11,214 6.41 (6.3-6.5) Brain Brain All Other Central Nervous System 540 5.78 (5.3-6.3) 110,541 6.03 (5.9-6.1) Meninges 20 0.21 (0.1-0.3) 190 0.11 (0.1-0.1) Brain All Meninges 20 0.21 (0.1-0.3) 190 0.11 (0.1-0.1) Brain All Meninges 20 0.21 (0.1-0.3) 190 0.11 (0.1-0.1) All Meninges 20 0.21 (0.1-0.3) 190 0.11 (0.2-0.3) All Meninges 20 0.02	Urinary Bladder		23.86	(22.8-24.9)		20.01	(19.8-20.2)
Ureter 38 0.44 (0.3-0.6) 877 0.53 (0.5-0.6) Other Urinary Organs 22 0.23 (0.1-0.4) 578 0.35 (0.3-0.4) Eye and Orbit 50 0.54 (0.4-0.7) 1.376 0.79 (0.7-0.8) Brain and Other Central Nervous System 580 6.21 (5.7-6.8) 11,214 6.41 (6.3-6.5) Brain and Other Central Nerves, System 580 6.21 (5.7-6.8) 11,214 6.41 (6.3-6.5) Meninges 20 0.21 (0.1-0.3) 190 0.11 (0.1-0.1) Spinal Cord, Cranial Nerves, & Other Parts of CNS 20 0.22 (0.1-0.4) 483 0.27 (0.2-0.3) Endocrine System 757 7.77 (7.2-8.4) 13.03 0.2-0 11,885 6.58 (6.5-6.7) 11,885 6.58 (6.5-6.7) 11,885 6.58 (6.5-6.7) 11,885 6.58 (6.5-6.7) 11,885 6.58 (6.5-6.7) 11,812 10,90 0.03 0.2-0.5	Kidney	1,014	10.96	(10.3-11.7)	16,592	9.85	(9.7-10.0)
Other Urinary Organs 22 0.23 (0.1-0.4) 578 0.35 (0.3-0.4) Eye and Orbit 50 0.54 (0.4-0.7) 1,376 0.79 (0.7-0.8) Brain and Other Central Nervous System 580 6.21 (5.7-6.8) 11,214 6.41 6.03 (5.9-6.1) Brain Meninges 20 0.21 (0.1-0.3) 190 0.11 (0.1-0.1) Spinal Cord, Cranial Nerves, & Other Parts of CNS 20 0.22 (0.1-0.4) 483 0.27 (0.2-0.3) Endocrine System 757 7.77 (7.2-8.4) 13,034 7.22 (7.1-7.3) Thyroid Gland 696 7.12 (6.6-7.7) 11,885 6.58 (6.5-6.8) 6.65 (6.5-6.7) 11,815 6.58 (6.5-6.7) 11,815 6.58 (6.5-6.7) 11,815 6.58 (6.5-6.7) 11,815 6.58 (6.5-6.7) 11,815 6.58 (6.5-6.7) 11,815 6.58 (6.5-6.7) 11,815 6.58 6.58 (6.5-6.7) 11,815 (6.5-				(0.7-1.1)			
Eye and Orbit 50 0.54 (0.4-0.7) 1,376 0.79 (0.7-0.8) Brain and Other Central Nervous System 580 6.21 (5.7-6.8) 11,214 6.41 (6.3-6.5) Brain Brain 540 5.78 (5.3-6.3) 11,214 6.41 (6.3-6.5) Meninges 20 0.21 (0.1-0.3) 190 0.11 (0.1-0.1) Spinal Cord, Cranial Nerves, & Other Parts of CNS 20 0.22 (0.1-0.4) 483 0.27 (0.2-0.3) Endocrine System 757 7.77 (7.2-8.4) 13,034 7.22 (7.1-7.3) Thyroid Gland 696 7.12 (6.6-7.7) 11,885 6.58 (6.5-6.7) Adrenal Gland 30 0.33 (0.2-0.5) 636 0.36 (0.3-0.3) Other Endocrine (Including Thymus) 31 0.32 (0.2-0.5) 636 0.36 (0.3-0.3) Molty Eymphoma 131 4.20 (1.9-2.5) 5.019 2.71 (2.6-2.8) Non-Hodgkin's Lymphoma			0.44	(0.3-0.6)		0.53	(0.5-0.6)
Brain and Other Central Nervous System 580 6.21 (5.7-6.8) 11,214 6.41 (6.3-6.5) Brain Meninges 540 5.78 (5.3-6.3) 10,541 6.03 (5.9-6.1) Spinal Cord, Cranial Nerves, & Other Parts of CNS 20 0.22 (0.1-0.4) 483 0.27 (0.2-0.3) Endocrine System 757 7.77 (7.2-8.4) 13,034 7.22 (7.1-7.3) Thyroid Gland 696 7.12 (6.6-7.7) 11,885 6.58 (6.5-6.7) Adrenal Gland 30 0.33 (0.2-0.5) 513 0.28 (0.3-0.3) Hodgkin's Lymphoma 214 2.20 (1.9-2.5) 5.019 2.71 (2.6-2.8) Non-Hodgkin's Lymphoma 1,316 14.65 (13.9-15.5) 32.597 19.13 (18.9-19.3) Multiple Myeloma 372 4.20 (1.9-2.5) 5.019 2.71 (2.6-2.8) Non-Hodgkin's Lymphomy 1,316 14.65 (1.3-12.8) 2.9.646 12.0 (1.9-13.9) <t< td=""><td>Other Urinary Organs</td><td></td><td></td><td>(0.1-0.4)</td><td></td><td></td><td></td></t<>	Other Urinary Organs			(0.1-0.4)			
Brain Meninges 540 5.78 (5.3-6.3) 10,541 6.03 (5.9-6.1) Spinal Cord, Cranial Nerves, & Other Parts of CNS 20 0.21 (0.1-0.3) 190 0.11 (0.1-0.3) Endocrine System 757 7.77 (7.2-8.4) 13,034 7.22 (7.1-7.3) Thyroid Gland 696 7.12 (6.6-7.7) 11,885 6.58 (6.5-6.7) Adrenal Gland 30 0.33 (0.2-0.5) 513 0.28 (0.3-0.3) Other Endocrine (Including Thymus) 31 0.32 (0.2-0.5) 513 0.28 (0.3-0.3) Modgkin's Lymphoma 214 2.20 (1.9-2.5) 5,019 2.71 (2.6-2.8) Multiple Myeloma 37 4.20 (3.8-4.7) 9,106 5.47 (5.4-5.8) Leukemia 1,059 12.05 (11.3-12.8) 20,646 12.06 (11.9-12.2) Lymphocytic 451 5.03 (4.6-5.5) 8,924 5.18 (5.1-5.3) Acute Lymphocytic 278<	·			(0.4-0.7)			
Meninges Spinal Cord, Cranial Nerves, & Other Parts of CNS 20 0.21 (0.1-0.3) 190 0.11 (0.1-0.1) Endocrine System 757 7.77 7.72-84 13,034 7.22 (0.1-0.3) Thyroid Gland 696 7.12 (6.6-7.7) 11,885 6.58 (6.5-6.7) Adrenal Gland 30 0.33 (0.2-0.5) 513 0.28 (0.3-0.3) Other Endocrine (Including Thymus) 31 0.32 (0.2-0.5) 636 0.36 (0.3-0.4) Hodgkin's Lymphoma 1,316 14.65 (13.9-15.5) 32,597 19.13 (18.9-19.3) Multiple Myeloma 372 4.20 (1.9-2.5) 5,019 2.71 (2.6-2.8) Leukemia 1,059 12.05 (11.3-12.8) 20.646 12.06 (11.9-12.2) Leukemia 1,059 12.05 (11.3-12.8) 20.646 12.06 (11.9-12.2) Leukemia 1,059 12.05 (11.3-12.8) 20.646 12.06 (11.9-12.2) Leukemia	•			, ,			, ,
Spinal Cord, Cranial Nerves, & Other Parts of CNS 20 0.22 (0.1-0.4) 483 0.27 (0.2-0.3) Endocrine System 757 7.77 (7.2-8.4) 13,034 7.22 (7.1-7.3) Thyroid Gland 696 7.12 (6.6-7) 11,885 6.58 (0.3-0.3) Adrenal Gland 30 0.33 (0.2-0.5) 636 0.36 (0.3-0.4) Hodgkin's Lymphoma 214 2.20 (1.9-1.5) 5.09 2.71 (2.6-2.8) Non-Hodgkin's Lymphoma 1,316 14.65 (13.9-15.5) 32,597 19.13 (18.9-19.3) Multiple Myeloma 372 4.20 (13.8-4.7) 9,106 5.47 (5.4-5.6) Leukemia 1,059 12.05 (11.3-11.2) 2.046 12.06 (11.9-12.2) Acute Lymphocytic 451 5.03 (4.6-5.5) 8,924 5.18 (5.1-5.3) Acute Lymphocytic 278 3.23 (2.8-3.7) 5,798 3.49 (3.4-3.6) Other Lymphocytic <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>							
Endocrine System 757 7.77 (7.2-8.4) 13,034 7.22 (7.1-7.3) Thyroid Gland 696 7.12 (6.6-7.7) 11,885 6.58 (6.5-6.7) Adrenal Gland 30 0.33 (0.2-0.5) 513 0.28 (0.3-0.4) Hodgkin's Lymphoma 214 2.20 (1.9-2.5) 5.019 2.71 (2.6-2.8) Non-Hodgkin's Lymphoma 1,316 (16.5) (13.9-15.5) 32.597 19.13 (18.9-19.3) Multiple Myeloma 372 4.20 (3.8-4.7) 9,106 5.47 (5.4-5.6) Leukemia 1,059 12.05 (11.3-12.8) 20.646 12.06 (11.9-12.2) Lymphocytic 451 5.03 (4.6-5.5) 8,924 5.18 (5.1-5.3) Acute Lymphocytic 278 3.23 (2.8-3.7) 5,798 3.49 (3.4-3.6) Other Lymphocytic 32 0.36 (0.2-0.5) 296 0.18 (0.2-0.3) Granulocytic (Myeloid) #N/A #N/A<	· ·						, ,
Thyroid Gland 696 7.12 (6.6-7.7) 11,885 6.58 (6.5-6.7) Adrenal Gland 30 0.33 (0.2-0.5) 513 0.28 (0.3-0.3) Other Endocrine (Including Thymus) 31 0.32 (0.2-0.5) 636 0.36 (0.3-0.4) Hodgkin's Lymphoma 214 2.20 (1.9-2.5) 5,019 2.71 (2.6-2.8) Non-Hodgkin's Lymphoma 1,316 14.65 (13.9-15.5) 32,597 19.13 (18.9-19.3) Multiple Myeloma 372 4.20 (3.8-4.7) 9,106 5.47 (5.4-5.6) Leukemia 1,059 12.05 (11.3-12.8) 20,646 12.06 (11.9-12.2) Lymphocytic 451 5.03 (4.6-5.5) 8,924 5.18 (5.1-5.3) Acute Lymphocytic 278 3.23 (2.8-3.7) 5,798 3.49 (3.4-3.6) Other Lymphocytic 32 0.36 (0.2-0.5) 296 0.18 (0.2-0.2) Granulocytic (Myeloid) #N/A	·			, ,			
Adrenal Gland Other Endocrine (Including Thymus) 30 0.33 (0.2-0.5) 513 0.28 (0.3-0.3) Other Endocrine (Including Thymus) 31 0.32 (0.2-0.5) 506 0.36 (0.3-0.4) Hodgkin's Lymphoma 214 2.20 (1.9-2.5) 5019 2.71 (2.6-2.8) Non-Hodgkin's Lymphoma 1,316 14.65 (13.9-15.5) 32,597 19.13 (18.9-19.3) Multiple Myeloma 372 4.20 (3.8-4.7) 9,106 5.47 (5.4-5.6) Leukemia 1,059 12.05 (11.3-12.8) 20,646 12.06 (11.9-12.2) Lymphocytic 451 5.03 (4.6-5.5) 8,924 5.18 (5.1-5.6) Acute Lymphocytic 278 3.23 (2.8-3.7) 5,798 3.49 (3.4-3.6) Other Lymphocytic 32 0.36 (0.2-0.5) 296 0.18 (0.2-0.2) Granulocytic (Myeloid) 330 3.66 (3.3-4.1) 6,141 3.59 (3.5-3.7) Chronic Myel	•						
Other Endocrine (Including Thymus) 31 0.32 (0.2-0.5) 636 0.36 (0.3-0.4) Hodgkin's Lymphoma 214 2.20 (1.9-2.5) 5,019 2.71 (2.6-2.8) Non-Hodgkin's Lymphoma 1,316 14.65 (13.9-15.5) 32,597 19.13 (18.9-19.3) Multiple Myeloma 372 4.20 (3.8-4.7) 9,106 5.47 (5.4-5.6) Leukemia 1,059 12.05 (11.3-12.8) 20,646 12.06 (11.9-12.2) Lymphocytic 451 5.03 (4.6-5.5) 8,924 5.18 (5.1-5.3) Acute Lymphocytic 278 3.23 (2.8-3.7) 5,798 3.49 (3.4-3.6) Other Lymphocytic 32 0.36 (0.2-0.5) 296 0.18 (0.2-0.2) Granulocytic (Myeloid) #N/A #N/A #N/A 9,175 5.36 (5.3-5.5) Acute Myeloid 330 3.66 (3.3-4.1) 6,14 3.59 (3.5-3.7) Other Myeloid #N/A				, ,			
Hodgkin's Lymphoma 214 2.20 (1.9-2.5) 5,019 2.71 (2.6-2.8) Non-Hodgkin's Lymphoma 1,316 14.65 (13.9-15.5) 32,597 19.13 (18.9-19.3) Multiple Myeloma 372 4.20 (3.8-4.7) 9,106 5.47 (5.4-5.6) Leukemia 1,059 12.05 (11.3-12.8) 20,646 12.06 (11.9-12.2) Lymphocytic 451 5.03 (4.6-5.5) 8,924 5.18 (5.1-5.3) Acute Lymphocytic 278 3.23 (2.8-3.7) 5,798 3.49 (3.4-3.6) Other Lymphocytic 32 0.36 (0.2-0.5) 296 0.18 (0.2-0.2) Granulocytic (Myeloid) #N/A #N/A #N/A 9,175 5.36 (5.3-5.5) Acute Myeloid 330 3.66 (3.3-4.1) 6,141 3.59 (3.5-3.7) Chronic Myeloid #N/A #N/A #N/A #N/A 48/A 48/A 0.10 0.10-1.1) Monocytic <							, ,
Non-Hodgkin's Lymphoma 1,316 14.65 (13.9-15.5) 32,597 19.13 (18.9-19.3) Multiple Myeloma 372 4.20 (3.8-4.7) 9,106 5.47 (5.4-5.6) Leukemia 1,059 12.05 (11.3-12.8) 20,646 12.06 (11.9-12.2) Lymphocytic 451 5.03 (4.6-5.5) 8,924 5.18 (5.1-5.3) Acute Lymphocytic 141 1.44 (1.2-1.7) 2,830 1.51 (1.5-1.6) Chronic Lymphocytic 278 3.23 (2.8-3.7) 5,798 3.49 (3.4-3.6) Other Lymphocytic 32 0.36 (0.2-0.5) 296 0.18 (0.2-0.2) Granulocytic (Myeloid) #N/A #N/A #N/A 9,175 5.36 (5.3-5.5) Acute Myeloid 330 3.66 (3.3-4.1) 6,141 3.59 (3.5-3.7) Chronic Myeloid #N/A #N/A #N/A 4N/A 4N/A 40.4 16.8 (1.6-1.7) Acute Myeloid	, , ,			, ,			, ,
Multiple Myeloma 372 4.20 (3.8-4.7) 9,106 5.47 (5.4-5.6) Leukemia 1,059 12.05 (11.3-12.8) 20,646 12.06 (11.9-12.2) Lymphocytic 451 5.03 (4.6-5.5) 8,924 5.18 (5.1-5.3) Acute Lymphocytic 278 3.23 (2.8-3.7) 5,798 3.49 (3.4-3.6) Other Lymphocytic 32 0.36 (0.2-0.5) 296 0.18 (0.2-0.2) Granulocytic (Myeloid) #N/A #N/A #N/A 9,175 5.36 (5.3-5.5) Acute Myeloid 330 3.66 (3.3-4.1) 6,141 3.59 (3.5-3.7) Chronic Myeloid 108 1.27 (1.0-1.6) 2,871 1.68 (1.6-1.7) Other Myeloid #N/A #N/A #N/A 48/A 48/A 0.10 (0.1-0.1) Monocytic #N/A #N/A #N/A 48/A 48/A 163 0.10 (0.2-0.3) Chronic Monocytic	• • • • • • • • • • • • • • • • • • • •						
Leukemia 1,059 12.05 (11.3-12.8) 20,646 12.06 (11.9-12.2) Lymphocytic 451 5.03 (4.6-5.5) 8,924 5.18 (5.1-5.3) Acute Lymphocytic 141 1.44 (1.2-1.7) 2,830 1.51 (1.5-1.6) Chronic Lymphocytic 278 3.23 (2.8-3.7) 5,798 3.49 (3.4-3.6) Other Lymphocytic (Myeloid) 32 0.36 (0.2-0.5) 296 0.18 (0.2-0.2) Granulocytic (Myeloid) #N/A #N/A #N/A 9,175 5.36 (5.3-5.5) Acute Myeloid 330 3.66 (3.3-4.1) 6,141 3.59 (3.5-3.7) Chronic Myeloid 108 1.27 (1.0-1.6) 2,871 1.68 (1.6-1.7) Other Myeloid #N/A #N/A #N/A 48N/A 439 0.26 (0.2-0.3) Acute Myeloid #N/A #N/A #N/A 48N/A 463 0.10 (0.1-0.1) Monocytic #N/A	· · · · · · · · · · · · · · · · · · ·						, ,
Lymphocytic 451 5.03 (4.6-5.5) 8,924 5.18 (5.1-5.3) Acute Lymphocytic 141 1.44 (1.2-1.7) 2,830 1.51 (1.5-1.6) Chronic Lymphocytic 278 3.23 (2.8-3.7) 5,798 3.49 (3.4-3.6) Other Lymphocytic (Myeloid) 32 0.36 (0.2-0.5) 296 0.18 (0.2-0.2) Granulocytic (Myeloid) #N/A #N/A #N/A 9,175 5.36 (5.3-5.5) Acute Myeloid 330 3.66 (3.3-4.1) 6,141 3.59 (3.5-3.7) Chronic Myeloid 108 1.27 (1.0-1.6) 2,871 1.68 (1.6-1.7) Other Myeloid #N/A #N/A #N/A #N/A 48/A 439 0.26 (0.2-0.3) Acute Monocytic #N/A #N/A #N/A #N/A 48/A 439 0.26 (0.2-0.3) Acute Monocytic 17 0.19 (0.1-0.3) 407 0.24 (0.2-0.3)	• •						
Acute Lymphocytic 141 1.44 (1.2-1.7) 2,830 1.51 (1.5-1.6) Chronic Lymphocytic 278 3.23 (2.8-3.7) 5,798 3.49 (3.4-3.6) Other Lymphocytic 32 0.36 (0.2-0.5) 296 0.18 (0.2-0.2) Granulocytic (Myeloid) #N/A #N/A #N/A 9,175 5.36 (5.3-5.5) Acute Myeloid 330 3.66 (3.3-4.1) 6,141 3.59 (3.5-3.7) Chronic Myeloid 108 1.27 (1.0-1.6) 2,871 1.68 (1.6-1.7) Other Myeloid #N/A #N/A #N/A #N/A 163 0.10 (0.1-0.1) Monocytic #N/A #N/A #N/A #N/A 439 0.26 (0.2-0.3) Acute Monocytic #N/A #N/A #N/A #N/A 439 0.26 (0.2-0.3) Chronic Monocytic #N/A #N/A #N/A #N/A #N/A 18 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A #N/A #N/A 18 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other Acute 49 0.61 (1.3-1.9) 2,108 1.26 (1.2-1.3) Other Acute 49 0.61 (0.4-0.8) 775 0.47 (0.4-0.5) Other Chronic MNOS 81 1.01 (0.8-1.3) 1,283 0.76 (0.7-0.8)							
Chronic Lymphocytic Other Lymphocytic 278 3.23 (2.8-3.7) 5,798 3.49 (3.4-3.6) Other Lymphocytic 32 0.36 (0.2-0.5) 296 0.18 (0.2-0.2) Granulocytic (Myeloid) #N/A #N/A #N/A 9,175 5.36 (5.3-5.5) Acute Myeloid 330 3.66 (3.3-4.1) 6,141 3.59 (3.5-3.7) Chronic Myeloid 108 1.27 (1.0-1.6) 2,871 1.68 (1.6-1.7) Other Myeloid #N/A #N/A #N/A #N/A 163 0.10 (0.1-0.1) Monocytic #N/A #N/A #N/A 439 0.26 (0.2-0.3) Acute Monocytic #N/A #N/A #N/A 407 0.24 (0.2-0.3) Chronic Monocytic #N/A #N/A #N/A 18 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other Monocytic #N/A				, ,			, ,
Other Lymphocytic 32 0.36 (0.2-0.5) 296 0.18 (0.2-0.2) Granulocytic (Myeloid) #N/A #N/A #N/A 9,175 5.36 (5.3-5.5) Acute Myeloid 330 3.66 (3.3-4.1) 6,141 3.59 (3.5-3.7) Chronic Myeloid 108 1.27 (1.0-1.6) 2,871 1.68 (1.6-1.7) Other Myeloid #N/A #N/A #N/A #N/A 163 0.10 (0.1-0.1) Monocytic #N/A #N/A #N/A 4N/A 439 0.26 (0.2-0.3) Chronic Monocytic 17 0.19 (0.1-0.3) 407 0.24 (0.2-0.3) Other Monocytic #N/A #N/A #N/A 18 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other 130 1.61 (1.3-1.9)							,
Granulocytic (Myeloid) #N/A #N/A #N/A 9,175 5.36 (5.3-5.5) Acute Myeloid 330 3.66 (3.3-4.1) 6,141 3.59 (3.5-3.7) Chronic Myeloid 108 1.27 (1.0-1.6) 2,871 1.68 (1.6-1.7) Other Myeloid #N/A #N/A #N/A 163 0.10 (0.1-0.1) Monocytic #N/A #N/A #N/A 439 0.26 (0.2-0.3) Acute Monocytic 17 0.19 (0.1-0.3) 407 0.24 (0.2-0.3) Chronic Monocytic #N/A #N/A #N/A 18 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other 130 1.61 (1.3-1.9) 2,108 1.26 (1.2-1.3) Other Chronic 49 0.61 (0.4-0.8) 775							, ,
Acute Myeloid 330 3.66 (3.3-4.1) 6,141 3.59 (3.5-3.7) Chronic Myeloid 108 1.27 (1.0-1.6) 2,871 1.68 (1.6-1.7) Other Myeloid #N/A #N/A #N/A #N/A 163 0.10 (0.1-0.1) Monocytic #N/A #N/A #N/A #N/A 439 0.26 (0.2-0.3) Acute Monocytic 17 0.19 (0.1-0.3) 407 0.24 (0.2-0.3) Chronic Monocytic #N/A #N/A #N/A #N/A 18 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other Acute 49 0.61 (1.3-1.9) 2,108 1.26 (1.2-1.3) Other Acute 49 0.61 (0.4-0.8) 775 0.47 (0.4-0.5) Other Chronic #N/A #N/A #N/A #N/A #N/A 50 0.03 (0.0-0.0) Aleukemic, Subleukemic and NOS 81 1.01 (0.8-1.3) 1,283 0.76 (0.7-0.8)							
Chronic Myeloid 108 1.27 (1.0-1.6) 2,871 1.68 (1.6-1.7) Other Myeloid #N/A #N/A #N/A 163 0.10 (0.1-0.1) Monocytic #N/A #N/A #N/A 439 0.26 (0.2-0.3) Acute Monocytic 17 0.19 (0.1-0.3) 407 0.24 (0.2-0.3) Chronic Monocytic #N/A #N/A #N/A 18 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other Monocytic #N/A 4N/A #N/A #N/A 14 0.01 (0.0-0.0) Other Monocytic #N/A 49 0.61 (0.4-							, ,
Other Myeloid #N/A #N/A #N/A #N/A 48/A 439 0.26 (0.1-0.1) Monocytic #N/A #N/A #N/A 439 0.26 (0.2-0.3) Acute Monocytic 17 0.19 (0.1-0.3) 407 0.24 (0.2-0.3) Chronic Monocytic #N/A #N/A #N/A 18 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other 130 1.61 (1.3-1.9) 2,108 1.26 (1.2-1.3) Other Chronic #N/A #N/A				,			,
Monocytic #N/A #N/A #N/A 439 0.26 (0.2-0.3) Acute Monocytic 17 0.19 (0.1-0.3) 407 0.24 (0.2-0.3) Chronic Monocytic #N/A #N/A #N/A 18 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other 130 1.61 (1.3-1.9) 2,108 1.26 (1.2-1.3) Other Acute 49 0.61 (0.4-0.8) 775 0.47 (0.4-0.5) Other Chronic #N/A #N/A #N/A 50 0.03 (0.0-0.0) Aleukemic, Subleukemic and NOS 81 1.01 (0.8-1.3) 1,283 0.76 (0.7-0.8)							
Acute Monocytic 17 0.19 (0.1-0.3) 407 0.24 (0.2-0.3) Chronic Monocytic #N/A #N/A #N/A 18 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other 130 1.61 (1.3-1.9) 2,108 1.26 (1.2-1.3) Other Acute 49 0.61 (0.4-0.8) 775 0.47 (0.4-0.5) Other Chronic #N/A #N/A #N/A 50 0.03 (0.0-0.0) Aleukemic, Subleukemic and NOS 81 1.01 (0.8-1.3) 1,283 0.76 (0.7-0.8)							, ,
Chronic Monocytic #N/A #N/A #N/A 18 0.01 (0.0-0.0) Other Monocytic #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other 130 1.61 (1.3-1.9) 2,108 1.26 (1.2-1.3) Other Acute 49 0.61 (0.4-0.8) 775 0.47 (0.4-0.5) Other Chronic #N/A #N/A #N/A 50 0.03 (0.0-0.0) Aleukemic, Subleukemic and NOS 81 1.01 (0.8-1.3) 1,283 0.76 (0.7-0.8)	•						, ,
Other Monocytic #N/A #N/A #N/A 14 0.01 (0.0-0.0) Other 130 1.61 (1.3-1.9) 2,108 1.26 (1.2-1.3) Other Acute 49 0.61 (0.4-0.8) 775 0.47 (0.4-0.5) Other Chronic #N/A #N/A #N/A 50 0.03 (0.0-0.0) Aleukemic, Subleukemic and NOS 81 1.01 (0.8-1.3) 1,283 0.76 (0.7-0.8)				, ,			, ,
Other 130 1.61 (1.3-1.9) 2,108 1.26 (1.2-1.3) Other Acute 49 0.61 (0.4-0.8) 775 0.47 (0.4-0.5) Other Chronic #N/A #N/A #N/A 50 0.03 (0.0-0.0) Aleukemic, Subleukemic and NOS 81 1.01 (0.8-1.3) 1,283 0.76 (0.7-0.8)	•						, ,
Other Acute 49 0.61 (0.4-0.8) 775 0.47 (0.4-0.5) Other Chronic #N/A #N/A #N/A 50 0.03 (0.0-0.0) Aleukemic, Subleukemic and NOS 81 1.01 (0.8-1.3) 1,283 0.76 (0.7-0.8)	·						,
Other Chronic #N/A #N/A #N/A 50 0.03 (0.0-0.0) Aleukemic, Subleukemic and NOS 81 1.01 (0.8-1.3) 1,283 0.76 (0.7-0.8)							, ,
Aleukemic, Subleukemic and NOS 81 1.01 (0.8-1.3) 1,283 0.76 (0.7-0.8)							,
	•	1,201	13.98	(13.2-14.8)	19,585		(11.6-11.9)

^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Table 6. Nevada Incidence by Type of Cancer and Gender, Nevada, 1997-2001

	Total	*	Mal	е	Fema	ale
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**
Total	40,863	453.43	21,042	496.69	19,821	423.04
Lip, Oral Cavity and Pharynx	994	10.62	695	15.28	299	6.33
Lip	49	0.53	44	0.98	5	
Base of Tongue	140	1.44	112	2.34	28	0.58
Other & Unspecified Parts of Tongue	154	1.62	107	2.30	47	0.97
Parotid Gland	69	0.77	44	1.10	25	0.52
Other & Unspecified Major Salivary glands	29	0.32	17	0.41	12	0.25
Floor of Mouth	85	0.93	53	1.18	32	0.70
Gum	21	0.23	9		12	0.25
Palate	39	0.41	19	0.39	20	0.43
Other & Unspecified Parts of Mouth	52	0.58	32	0.76	20	0.43
Nasopharynx	50	0.54	38	0.79	12	0.26
Tonsil	125	1.31	90	1.88	35	0.74
Oropharynx	44	0.47	34	0.78	10	0.20
Pyriform Sinus	46	0.49	35	0.76	11	0.24
Hypopharynx	33	0.35	24	0.50	9	
Other & Unspecified Oral (Buccal) Cavity & Pharynx	58	0.65	37	0.91	21	0.45
Digestive System	7,357	84.57	4,155	100.59	3,202	70.46
Esophagus	481	5.30	363	8.38	118	2.54
Stomach	565	6.67	368	9.14	197	4.48
Small Intestine	106	1.17	52	1.17	54	1.16
Colon (excluding Rectum)	3,213	37.79	1,686	42.23	1,527	33.99
Cecum	672	8.05	339	8.77	333	7.47
Appendix	35	0.39	17	0.36	18	0.39
Ascending Colon	424	5.09	214	5.43	210	4.76
Hepatic Flexure Transverse Colon	109 245	1.28 2.88	53 124	1.27 3.15	56	1.26 2.68
Splenic Flexure	245 91	1.03	47	1.20	121	
•					44	0.94
Descending Colon Sigmoid Colon	147 917	1.63 10.35	75 510	1.72 12.15	72 407	1.55 8.81
· ·	573	7.09	307	8.18	266	6.15
Large Intestine, NOS Rectum	770	7.09 8.62	446	10.58	324	6.15
Rectosigmoid Junction	421	4.68	248	5.70	173	3.73
Anus, Anal Canal and Anorectum	126	1.34	39	0.82	87	1.84
Liver	442	4.87	305	6.81	137	2.98
Intrahepatic Bile Ducts	73	0.85	42	1.05	31	0.68
Gallbladder	61	0.74	17	0.43	44	0.99
Other & Unspecified Biliary Tract	100	1.20	57	1.46	43	0.97
Pancreas	951	10.84	502	12.18	449	9.75
Retroperitoneum	32	0.35	21	0.45	11	0.24
Peritoneum, Omentum and Mesentery	3		2		1	
Other Digestive Organs	13	0.14	7		6	
Respiratory System	7,758	86.35	4,294	101.68	3,464	73.76
Nasal Cavity and Middle Ear	31	0.36	19	0.51	12	0.25
Accessory Sinuses	23	0.24	15	0.31	8	
Larynx	348	3.78	276	6.18	72	1.55
Lung and Bronchus	7,336	81.77	3,970	94.37	3,366	71.68
Pleura	3		2		1	
Trachea	4		3		1	
Mediastinum and Other Respiratory Organs	13	0.13	9		4	
Bones, Joints and Articular Cartilage	90	0.95	50	1.00	40	0.87
Bones, Joints & Articular Cartilage of Limbs	43	0.46	20	0.40	23	0.50
Bones, Joints & Articular Cartilage of Other & Unspec Sites	47	0.49	30	0.60	17	0.37
Soft Tissue (Including Heart)	215	2.32	124	2.72	91	1.93
Heart	1		0		1	
Peripheral Nerves & Autonomic Nervous System	8		4		4	
Connective, Subcutaneous & Other Soft Tissues	206	2.23	120	2.64	86	1.83

^{*} Those of unknown gender are not shown separately, but are included in the total.

^{**} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Table 6. Nevada Incidence by Type of Cancer and Gender, Nevada, 1997-2001 (Continued)

	Tota	 *	Mal	е	Fema	ale
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**
Total	40,863	453.43	21,042	496.69	19,821	423.04
Skin (Excluding Basal And Squamous)	1,189	12.82	699	15.74	490	10.35
Melanomas Of The Skin	1,083	11.59	634	14.09	449	9.45
Other Non-Epithelial Skin	106	1.23	65	1.65	41	0.90
Breast	6,493	70.45	73	1.82	6,420	135.20
Female Genital System	2,250	24.38	0		2,250	47.38
Cervix Uteri	497	5.22	0		497	10.39
Corpus Uteri	808	8.75	0		808	16.94
Uterus, NOS	44	0.52	0		44	0.96
Ovary	737	8.02	0		737	15.54
Vagina	39	0.43	0		39	0.83
Vulva	112	1.30	0		112	2.45
Placenta	1		0		1	
Other Female Genital Organs	12	0.12	0		12	0.24
Male Genital System	5,605	61.36	5,605	131.04	0	
Prostate	5,337	58.64	5,337	125.66	0	
Testis	237	2.37	237	4.63	0	
Penis	19	0.22	19	0.48	0	
Other Male Genital Organs	12	0.13	12	0.27	0	
Urinary System	3,218	36.33	2,317	56.15	901	19.49
Urinary Bladder	2,068	23.86	1,567	39.31	501	11.00
Kidney	1,014	10.96	656	14.55	358	7.60
Renal Pelvis	76	0.84	50	1.19	26	0.55
Ureter	38	0.44	28	0.74	10	0.21
Other Urinary Organs	22	0.23	16	0.36	6	
Eye and Orbit	50	0.54	29	0.65	21	0.44
Brain and Other Central Nervous System	580	6.21	338	7.36	242	5.11
Brain	540	5.78	316	6.90	224	4.73
Meninges	20	0.21	9		11	0.23
Spinal Cord, Cranial Nerves, & Other Parts of CNS	20	0.22	13	0.27	7	
Endocrine System	757	7.77	190	4.09	567	11.71
Thyroid Gland	696	7.12	157	3.29	539	11.15
Adrenal Gland	30	0.33	17	0.44	13	0.26
Other Endocrine (Including Thymus)	31	0.32	16	0.35	15	0.30
Hodgkin's Lymphoma	214	2.20	117	2.32	97	2.03
Non-Hodgkin's Lymphoma	1,316	14.65	737	17.38	579	12.42
Multiple Myeloma	372	4.20	216	5.32	156	3.33
Leukemia	1,059	12.05	629	14.97	430	9.44
Lymphocytic	451	5.03	280	6.62	171	3.68
Acute Lymphocytic	141	1.44	82	1.65	59	1.23
Chronic Lymphocytic	278	3.23	171	4.34	107	2.34
Other Lymphocytic	32	0.36	27	0.63	5	
Myeloid and Monocytic	478	5.40	276	6.42	202	4.43
Acute Myeloid	330	3.66	185	4.21	145	3.13
Acute Monocytic	17	0.19	9		8	
Chronic Myeloid	108	1.27	68	1.65	40	0.91
Other Myeloid/Monocytic	23	0.28	14	0.35	9	4 22
Other	130	1.61	73	1.94	57	1.33
Other Acute	49	0.61	30	0.83	19	0.43
Aleukemic, Subleukemic and NOS	81	1.01	43	1.11	38	0.90
Mesothelioma	91	1.08	71	1.97	20	0.42
Kaposi Sarcoma	54	0.58	52	1.15	2	40.00
Other, Ill-Defined and Unspecified Sites	1,201	13.98	651	15.46	550	12.32

^{*} Those of unknown gender are not shown separately, but are included in the total.

^{**} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Table 7. Nevada Incidence by Type of Cancer and Stage of Cancer, Nevada, 1997-2001

Time of Conces	Total	In situ	Localized	Pagional	Distant	Unstaged
Type of Cancer	Total			Regional	Distant	
Total	40,863	1,560	15,503	7,420	7,688	8,692
Lip, Oral Cavity and Pharynx	994	0	322	372	90	210
Lip	49	0	37	5	2	5
Base of Tongue	140	0	23	84	11	22
Other & Unspecified Parts of Tongue	154	0	73	33	12	36
Parotid Gland	69	0	33	18	2	16
Other & Unspecified Major Salivary glands	29	0	8	12	2	7
Floor of Mouth	85	0	40	27	9	9
Gum Palate	21	0	6 22	8	3	4
Other & Unspecified Parts of Mouth	39 52	0	15	8 18	4 6	5 13
Nasopharynx	50	0	5	19	7	19
Tonsil	125	0	26	67	7	25
Oropharynx	44	0	7	11	12	14
Pyriform Sinus	46	0	9	27	4	6
Hypopharynx	33	0	13	9	2	9
Other & Unspecified Oral (Buccal) Cavity & Pharynx	58	0	5	26	7	20
Digestive System	7,357	0	1,805	2,286	1,565	1,701
Esophagus	481	0	74	99	119	189
Stomach	565	0	101	175	141	148
Small Intestine	106	0	23	36	31	16
Colon (excluding Rectum)	3,213	0	909	1,207	636	461
Cecum	672	0	181	296	151	44
Appendix	35	0	11	11	10	3
Ascending Colon	424	0	136	193	69	26
Hepatic Flexure	109	0	32	50	21	6
Transverse Colon	245	0	73	112	48	12
Splenic Flexure	91	0	33	48	7	3
Descending Colon	147	0	46	55	36	10
Sigmoid Colon	917	0	332	368 74	171	46
Large Intestine, NOS Rectum	573 770	0	65 280	239	123 116	311 135
Rectosigmoid Junction	421	0	136	169	83	33
Anus, Anal Canal and Anorectum	126	0	67	23	15	21
Liver	442	0	84	29	77	252
Intrahepatic Bile Ducts	73	0	13	14	11	35
Gallbladder	61	0	18	21	18	4
Other & Unspecified Biliary Tract	100	0	22	28	15	35
Pancreas	951	0	69	240	290	352
Retroperitoneum	32	0	9	5	6	12
Peritoneum, Omentum and Mesentery	3	0	0	1	2	0
Other Digestive Organs	13	0	0	0	5	8
Respiratory System	7,758	0	1,338	1,493	2,598	2,329
Nasal Cavity and Middle Ear	31	0	15	2	3	11
Accessory Sinuses	23	0	8	9	5	1
Larynx	348	0	135	78	24	111
Lung and Bronchus	7,336	0	1,176	1,401	2,563	2,196
Pleura	3	0	0	0	0	3
Trachea	4	0	0	2	1	1
Mediastinum and Other Respiratory Organs	13	0	4	1	2	6
Bones, Joints and Articular Cartilage Bones, Joints & Articular Cartilage of Limbs	90 43	0	32 23	11 4	18 5	29 11
Bones, Joints & Articular Cartilage of Other & Unspec Sites	43 47	0	23 9	7	13	18
Soft Tissue (Including Heart)	215	0	92	11	29	83
Heart	1	0	1	0	0	0
Peripheral Nerves & Autonomic Nervous System	8	0	2	1	0	5
Connective, Subcutaneous & Other Soft Tissues	206	0	89	10	29	78

Table 7. Nevada Incidence by Type of Cancer and Stage of Cancer, Nevada, 1997-2001 (Continued)

Type of Cancer	Total	In situ	Localized	Regional	Distant	Unstaged
Total	40,863	1,560	15,503	7,420	7,688	8,692
Total	40,003	1,500	13,303	1,420	7,000	0,032
Skin (Excluding Basal And Squamous)	1,189	0	836	86	76	191
Melanomas Of The Skin	1,083	0	770	77	69	167
Other Non-Epithelial Skin	106	0	66	9	7	24
Breast	6,493	958	3,090	1,563	315	567
Female Genital System	2,250	0	1,127	412	472	239
Cervix Uteri	497	0	241	157	49	50
Corpus Uteri	808	0	616	92	44	56
Uterus, NOS	44	0	13	6	9	16
Ovary	737	0	162	124	352	99
Vagina	39	0	16	7	9	7
Vulva	112	0	76	24	3	9
Placenta	1	0	0	0	1	0
Other Female Genital Organs	12	0	3	2	5	2
Male Genital System	5,605	0	3,892	553	286	874
Prostate	5,337	0	3,726	516	247	848
Testis	237	0	150	35	38	14
Penis	19 12	0	9 7	1	1	8 4
Other Male Genital Organs		0				
Urinary System	3,218	602 602	1,616	325	256	419
Urinary Bladder	2,068		1,001	177	69	219
Kidney	1,014	0	538	117	179	180
Renal Pelvis Ureter	76 38	0	45 21	20 5	5 2	6 10
Other Urinary Organs	22	0	11	6	1	4
Eye and Orbit	50	0	12	0	1	37
Brain and Other Nervous System	580	0	381	14	6	179
Brain	540	0	368	12	5	179
Meninges	20	0	10	1	1	8
Spinal Cord, Cranial Nerves, & Other Parts of CNS	20	0	3	1	0	16
Endocrine System	757	0	485	142	43	87
Thyroid Gland	696	0	465	136	34	61
Adrenal Gland	30	0	8	4	7	11
Other Endocrine (Including Thymus)	31	0	12	2	2	15
Hodgkin's Lymphoma	214	0	83	30	51	50
Non-Hodgkin's Lymphoma	1,316	0	359	112	426	419
Multiple Myeloma	372	0	1	0	353	18
Leukemia	1,204	0	32	9	1,043	120
Lymphocytic	451	0	0	0	447	4
Acute Lymphocytic	141	0	0	0	141	0
Chronic Lymphocytic	278	0	0	0	275	3
Other Lymphocytic	32	0	0	0	31	1
Myeloid and Monocytic	478	0	Ö	Ö	468	10
Acute Myeloid	330	0	0	0	323	7
Acute Monocytic	17	0	0	0	17	0
Chronic Myeloid	108	0	0	0	107	1
Other Myeloid/Monocytic	23	0	0	0	21	2
Other	130	0	0	0	99	31
Other Acute	49	0	0	0	41	8
Aleukemic, Subleukemic and NOS	81	0	0	0	58	23
Mesothelioma	91	0	18	8	15	50
Kaposi Sarcoma	54	0	14	1	14	25
Other, Ill-Defined and Unspecified Sites	1,201	0	0	1	60	1,140
Carea, an Dominos and Oriopositios Ottos	1,201					1,170

Table 8. Top Ten Types of Cancer Incidence by County/Region of Residence, Nevada Residents, 1997-2001

				County/Regio	n of Residence	
Rank	Type of Cance	Nevada Total	Clark	Washoe	All Other Counties	
1	Lung and Bronchus	Incidence	7,336	5,117	1,102	1,113
		Rate*	81.77	85.42	74.29	74.69
		95% C.I.	(79.9-83.7)	(83.0-87.9)	(69.9-78.9)	(70.3-79.3)
2	Breast*	Incidence	6,420	4,274	1,254	889
		Rate*	135.20	134.37	154.28	118.04
		95% C.I.	(131.9-138.6)	(130.3-138.5)	(145.8-163.1)	(110.4-126.1)
3	Prostate*	Incidence	5,337	3,408	1,053	874
		Rate*	125.66	119.84	151.02	123.95
		95% C.I.	(122.1-129.4)	(115.5-124.3)	(141.6-161.0)	(115.5-133.0)
4	Colorectal	Incidence	4,530	3,118	775	637
		Rate*	52.43	54.15	53.32	44.71
		95% C.I.	(50.9-54.0)	(52.2-56.2)	(49.6-57.3)	(41.2-48.4)
5	Urinary Bladder	Incidence	2,068	1,376	337	354
		Rate*	23.86	23.79	23.12	24.68
		95% C.I.	(22.8-24.9)	(22.5-25.1)	(20.7-25.8)	(22.1-27.5)
6	Non-Hodgkin's Lymphoma	Incidence	1,316	839	259	217
		Rate*	14.65	14.10	16.86	14.84
		95% C.I.	(13.9-15.5)	(13.1-15.1)	(14.8-19.1)	(12.9-17.0)
7	Kidney and Renal Pelvis	Incidence	1,090	711	204	174
		Rate*	11.80	11.49	13.07	11.78
		95% C.I.	(11.1-12.5)	(10.6-12.4)	(11.3-15.0)	(10.1-13.7)
8	Leukemia	Incidence	1,059	742	163	153
		Rate*	12.05	12.64	10.90	10.94
		95% C.I.	(11.3-12.8)	(11.7-13.6)	(9.3-12.8)	(9.2-12.9)
9	Lip, Oral Cavity and Pharynx	Incidence	994	670	180	
		Rate*	10.62	10.68	11.50	
		95% C.I.	(10.0-11.3)	(9.9-11.6)	(9.9-13.4)	
10	Pancreas	Incidence	951		154	150
		Rate*	10.84		10.49	10.42
		95% C.I.	(10.1-11.6)		(8.9-12.3)	(8.8-12.3)
	Total	Incidence	40,863	27,522	7,239	6,080
		Rate*	453.43	456.94	476.32	415.82
		95% C.I.	(448.9-457.9)	(451.4-462.5)	(465.3-487.6)	(405.3-426.6)

^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" indicates that this type of cancer was not in the Top Ten for this specific region.

Table 9. Top Ten Types of Cancer Incidence by Age Group, Nevada Residents, 1997-2001

Ranking					Age Group				
Kalikiliy	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75+	Total
1	Leukemia	Thyroid Gland	Thyroid Gland	Breast	Breast	Lung and Bronchus	Lung and Bronchus	Lung and Bronchus	Lung and Bronchus
	115	42	125	668	1,393	1,699	2,806	2,052	7,336
	39.4%	14.6%	14.5%	29.5%	26.3%	18.5%	22.5%	20.2%	18.0%
2	Brain and OCNS	HL	Breast	Thyroid Gland	Lung and Bronchus	Breast	Prostate	Colorectal	Breast
	53	33	106	165	627	1,578	2,225	1,532	6,493
	18.2%	11.5%	12.3%	7.3%	11.8%	17.2%	17.8%	15.1%	15.9%
3	NHL	Leukemia	Skin	Colorectal	Colorectal	Prostate	Breast	Prostate	Prostate
	17	30	75	157	458	1,456	1,564	1,249	5,337
	5.8%	10.5%	8.7%	6.9%	8.6%	15.9%	12.5%	12.3%	13.1%
4	KRP	Skin	NHL	Skin	Prostate	Colorectal	Colorectal	Breast	Colorectal
	15	27	63	156	381	898	1,444	1,171	4,530
	5.1%	9.4%	7.3%	6.9%	7.2%	9.8%	11.6%	11.5%	11.1%
5	Liver and IBD	Brain and OCNS	Cervix Uteri	Lung and Bronchus	Skin	Urinary Bladder	Urinary Bladder	Urinary Bladder	Urinary Bladder
	8	20	57	129	209	390	717	727	2,068
	2.7%	7.0%	6.6%	5.7%	3.9%	4.3%	5.7%	7.2%	5.1%
6	HL	NHL	HL	Cervix Uteri	NHL	LOCP	NHL	NHL	NHL
	7	17	49	120	199	312	342	343	1,316
	2.4%	5.9%	5.7%	5.3%	3.8%	3.4%	2.7%	3.4%	3.2%
7	LOCP	Ovary	Brain and OCNS	NHL	KRP	KRP	Pancreas	Pancreas	KRP
	4	7	43	90	174	290	304	304	1,090
	1.4%	2.4%	5.0%	4.0%	3.3%	3.2%	2.4%	3.0%	2.7%
8	Urinary Bladder	Cervix Uteri	Leukemia	Ovary	LOCP	NHL	KRP	Leukemia	Skin
	3	6	38	74	172	243	302	300	1,083
	1.0%	2.1%	4.4%	3.3%	3.2%	2.6%	2.4%	3.0%	2.7%
9	Thyroid Gland	Breast	Colorectal	KRP	Urinary Bladder	CU & Uterus NOS	LOCP	KRP	Leukemia
	2	4	34	71	167	213	273	225	1,059
	0.7%	1.4%	3.9%	3.1%	3.1%	2.3%	2.2%	2.2%	2.6%
10	Breast	LOCP	Ovary	Leukemia	Thyroid Gland	Pancreas	Leukemia	Stomach	LOCP
	1	4	34	59	166	210	261	215	994
	0.3%	1.4%	3.9%	2.6%	3.1%	2.3%	2.1%	2.1%	2.4%
Sum	225	190	624	1,689	3,946	7,289	10,238	8,118	31,306
Percent	77.1%	66.2%	72.3%	74.7%	74.4%	79.4%	81.9%	80.0%	76.6%
Total	292	287	863	2,262	5,302	9,176	12,497	10,142	40,863
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Abbreviations: Brain and OCNS = Brain and Other Central Nervous System, CU & Uterus NOS = Corpus Uteri and Uterus NOS, HL = Hodgkin's Lymphoma, KRP = Kidney and Renal Pelvis, LOCP = Lip, Oral Cavity and Pharynx, Liver and IBD = Liver and Intrahepatic Bile Ducts, NHL = Non-Hodgkin's Lymphoma. Note: Those cases with unknown ages are not shown separately, but are included in the total.

Table 10. Median Age at Time of Diagnosis by Leading Types of Cancer and Race/Ethnicity, Nevada Residents, 1997-2001

						Race/E	thnicity					
Type of Cancer	Whi	te	Bla	ck	Native A	merican	As	ian	Hisp	anic	Tot	tal
	Number	Age	Number	Age	Number	Age	Number	Age	Number	Age	Number	Age
Lung and Bronchus	6,623	69.0	329	66.0	41	68.0	137	67.0	183	68.0	7,329	69.0
Breast	5,672	62.0	330	59.0	20	57.0	169	57.0	224	53.0	6,485	61.0
Prostate	4,686	68.0	326	66.0	23	70.0	77	67.0	174	68.0	5,327	68.0
Colorectal	4,022	70.0	224	67.0	15	64.0	106	64.0	129	67.0	4,525	70.0
Urinary Bladder	1,896	71.0	68	69.0	9	61.0	22	72.0	63	67.0	2,067	71.0
Non-Hodgkin's Lymphoma	1,175	66.0	44	54.0	5	41.0	29	63.0	55	59.0	1,314	65.0
Kidney and Renal Pelvis	942	64.0	63	61.0	8	70.5	19	64.0	50	65.0	1,089	64.0
Leukemia	919	68.0	39	59.0	3		24	58.5	68	35.0	1,058	66.0
Lip, Oral Cavity and Pharynx	886	62.0	42	62.0	5	61.0	13	66.0	35	56.0	993	62.0
Pancreas	817	69.0	61	67.0	5	67.0	18	69.0	47	66.0	951	69.0
Skin	1,030	58.0	17	62.0	4		4		23	49.0	1,082	58.0
Corpus Uteri & Uterus NOS	753	65.0	34	63.0	4		23	54.0	33	59.0	852	64.0
Ovary	648	63.0	32	60.0	5	55.0	18	63.0	29	43.0	737	62.0
Thyroid Gland	580	45.0	28	41.0	4		41	48.0	37	42.0	696	45.0
Stomach	474	71.0	30	67.0	2		23	72.0	33	65.0	564	71.0
Brain and Other Central Nervous System	493	59.0	21	57.0	2		20	55.0	40	38.0	580	58.0
Cervix Uteri	397	49.0	27	50.0	0		24	55.0	43	52.0	497	50.0
Liver and Intrahepatic Bile Ducts	406	68.0	36	63.5	4		39	57.0	29	60.0	515	67.0
Esophagus	420	67.5	34	64.0	2		10	63.0	14	61.0	481	67.0
Larynx	313	65.0	17	63.0	2		0		14	61.0	348	65.0
Multiple Myeloma	311	68.0	22	64.0	6	74.5	10	68.0	20	63.0	369	67.0
Hodgkin's Lymphoma	184	41.0	11	42.0	2		8	29.0	9	25.0	214	39.0
All Other Sites	2,392	66.0	149	62.0	14	64.5	44	62.5	138	54.0	2,748	65.0
Total	36,039	67.0	1,984	64.0	185	65.0	878	62.0	1,490	61.0	40,821	66.0

Note: Those of other/unknown race/ethnicity are not shown separately, but are included in the total. Those cases of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

INPATIENT HOSPITAL DISCHARGES HIGHLIGHTS

- ➤ Lung and Bronchus Cancer was the leading type of Cancer for inpatient discharges in Nevada from 1997 to 2001. This type of cancer accounted for 15.0% of all resident cancer inpatient hospital discharges. The second leading type of cancer was Colorectal Cancer, which accounted for 12.6% of all cancer inpatient discharges during this period.
- The two leading types of cancer for inpatient hospital discharges, Lung and Bronchus and Colorectal Cancer accounted for 305.2 million dollars in total billed amounts in Nevada from 1997 to 2001. This accounted for 32.8% of the total 1 billion dollars in billed amounts for cancer inpatient hospital discharges during this period.
- ➤ The five types of cancer that had the highest average total billed amount for Nevada from 1997 to 2001 were: Leukemia (\$60,984), Stomach (\$54,355), Esophagus (\$43,963), Ovary (\$41,285), and Larynx (\$41,256) Cancer.
- ➤ The five types of cancer that had the highest median total billed amount for Nevada from 1997 to 2001 were: Stomach (\$35,342), Larynx (\$30,842), Brain and Other Central Nervous System (\$30,345), Leukemia (\$29,255), and Colorectal (\$26,392) Cancer.
- ➤ The five types of cancer that had the highest average length of stay (days) for cancer inpatient hospital discharges for Nevada from 1997 to 2001 were: Leukemia (12.72), Stomach (11.07), Esophagus (10.01), Larynx (9.88), and Pancreas (9.58) Cancer.

Figure 9. Top Ten Leading Cancers in Total Inpatient Discharge Charges, Nevada Residents, 1997-2001




Figure 10. Top Ten Leading Cancers in Average Inpatient Discharge Charges, Nevada Residents, 1997-2001




Figure 11. Top Ten Leading Cancers in Median Inpatient Discharge Charges, Nevada Residents, 1997-2001




Figure 12. Top Ten Leading Cancers in Total Number of Days Stayed for Inpatient Hospital Discharges, Nevada Residents, 1997-2001




Figure 13. Top Ten Leading Cancers in Average Length of Stay (Days) for Inpatient Hospital Discharges, Nevada Residents, 1997-2001




Figure 14. Top Ten Leading Cancers in Median Length of Stay (Days) for Inpatient Hospital Discharges, Nevada Residents, 1997-2001




Table 11. Nevada Inpatient Hospital Discharges by Type of Cancer and Gender, Nevada, 1997-2001

	Total	*	Male)	Fema	emale	
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**	
Total	33,235	364.78	16,125	372.79	17,110	363.40	
Lip, Oral Cavity and Pharynx	526	5.55	352	7.59	174	3.64	
Lip	8		7		1		
Base of Tongue	79	0.81	50	1.02	29	0.60	
Other & Unspecified Parts of Tongue	97	1.03	61	1.34	36	0.75	
Parotid Gland	47	0.50	30	0.66	17	0.36	
Other & Unspecified Major Salivary glands	9		7		2		
Floor of Mouth	59	0.60	37	0.75	22	0.45	
Gum	27	0.30	17	0.36	10	0.22	
Palate	12	0.13	5		7		
Other & Unspecified Parts of Mouth	27	0.29	18	0.42	9		
Nasopharynx	23	0.24	17	0.35	6	0.24	
Tonsil	46	0.48	35	0.70	11	0.24	
Oropharynx	23	0.23	20	0.40	3		
Pyriform Sinus	20	0.21	16	0.36	4		
Hypopharynx Other & Unenseified Oral (Russel) Covity & Phanusy	25 24	0.28 0.26	15 17	0.32 0.40	10 7	0.22	
Other & Unspecified Oral (Buccal) Cavity & Pharynx Digestive System	6,591	75.45	3,624	87.08	2,967	65.08	
	297	3.23	224	5.07	2,967 73	1.56	
Esophagus Stomach	583	5.23 6.64	398	9.63	73 185	4.05	
Small Intestine	135	1.48	74	1.64	61	1.30	
Colon (excluding Rectum)	2,825	33.22	1,392	34.69	1,433	31.88	
Cecum	548	6.66	246	6.24	302	6.89	
Appendix	25	0.00	246	0.24	16	0.09	
	543	6.44	259	6.55	284		
Ascending Colon Hepatic Flexure	99	1.21	259 52	1.27	204 47	6.35 1.10	
•		2.95		3.09	130		
Transverse Colon Splenic Flexure	250 101	1.18	120 43	1.20	58	2.87 1.24	
Descending Colon	155	1.73	89	2.17	66	1.40	
Sigmoid Colon	793	9.14	421	10.21	372	8.20	
Large Intestine, NOS	311	3.63	153	3.77	158	3.50	
Rectum	662	7.52	377	9.02	285	6.21	
Rectoring Rector	576	6.41	329	7.51	247	5.34	
Anus, Anal Canal and Anorectum	133	1.47	71	1.68	62	1.32	
Liver	308	3.28	213	4.68	95	1.99	
Intrahepatic Bile Ducts	39	0.45	19	0.46	20	0.44	
Gallbladder	38	0.43	14	0.40	24	0.44	
Other & Unspecified Biliary Tract	145	1.73	76	2.03	69	1.52	
Pancreas	741	8.36	390	9.21	351	7.61	
Retroperitoneum	53	0.57	34	0.77	19	0.41	
Peritoneum, Omentum and Mesentery	52	0.56	11	0.23	41	0.86	
Other Digestive Organs	4		2	0.20	2		
Respiratory System	5,337	58.35	2,871	66.26	2,466	51.93	
Nasal Cavity and Middle Ear	3,337	0.12	2,071		2, 4 00	31.95	
Accessory Sinuses	17	0.18	12	0.25	5		
Larynx	203	2.18	160	3.60	43	0.90	
Lung and Bronchus	4,965	54.28	2,601	59.93	2,364	49.79	
Pleura	66	0.78	51	1.40	15	0.32	
Trachea	18	0.19	10	0.21	8		
Mediastinum and Other Respiratory Organs	57	0.19	31	0.73	26	0.54	
Bones, Joints and Articular Cartilage	116	1.23	56	1.15	60	1.29	
Bones, Joints & Articular Cartilage of Limbs	48	0.51	23	0.47	25	0.55	
Bones, Joints & Articular Cartilage of Other & Unspec Sites	68	0.71	33	0.67	35	0.74	
Soft Tissue (Including Heart)	125	1.38	61	1.47	64	1.36	
Heart	2	1.56	1	1.47	1	1.50	
Peripheral Nerves & Autonomic Nervous System	0		0		0		
Connective, Subcutaneous & Other Soft Tissues	123	1.36	60	1.45	63	1.34	

^{*} Those of unknown gender are not shown separately, but are included in the total.

^{**} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Table 11. Nevada Inpatient Hospital Discharges by Type of Cancer and Gender, Nevada, 1997-2001 (Continued)

Torre of O	Tota	 *	Mal	е	Fema	ale
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**
Total	33,235	364.78	16,125	372.79	17,110	363.40
Skin (Excluding Basal And Squamous)	240	2.72	152	3.68	88	1.92
Melanomas Of The Skin	83	0.91	54	1.28	29	0.61
Other Non-Epithelial Skin	157	1.81	98	2.40	59	1.31
Breast	2,608	28.45	19	0.52	2,589	54.69
Female Genital System	2,349	25.18	0		2,349	49.24
Cervix Uteri	646	6.65	0		646	13.39
Corpus Uteri	801	8.60	0		801	16.73
Uterus, NOS	27	0.30	0		27	0.58
Ovary	669	7.21	0		669	14.04
Vagina	53	0.59	0		53	1.13
Vulva	117	1.45	0		117	2.63
Placenta	1		0		1	
Other Female Genital Organs	35	0.36	0		35	0.71
Male Genital System	2,605	27.49	2,605	57.52	0	
Prostate	2,536	26.77	2,536	56.03	0	
Testis	51	0.51	51	0.98	0	
Penis	15	0.19	15	0.45	0	
Other Male Genital Organs	3		3		0	40.00
Urinary System	1,995	22.37	1,391	33.37	604	12.98
Urinary Bladder	1,022	11.93	762	19.40	260	5.76
Kidney	819	8.73	528	11.53	291	6.11
Renal Pelvis	86	0.96	58	1.44	28	0.58
Ureter	49	0.54	35	0.82	14	0.30
Other Urinary Organs Eye and Orbit	19 4	0.20	8 2		11 2	0.22
,						
Brain and Other Central Nervous System Brain	762 706	8.05 7.47	449 425	9.55 9.05	313 281	6.58 5.92
Meninges	37	0.39	14	0.31	23	0.47
Spinal Cord, Cranial Nerves, & Other Parts of CNS	19	0.39	10	0.20	9	0.47
Endocrine System	1,032	10.56	235	4.93	797	16.48
Thyroid Gland	985	10.06	216	4.93	769	15.92
Adrenal Gland	21	0.22	9	4.47	12	0.24
Other Endocrine (Including Thymus)	26	0.22	10	0.26	16	0.24
Hodgkin's Lymphoma	116	1.19	63	1.25	53	1.11
Non-Hodgkin's Lymphoma	988	11.01	550	12.84	438	9.44
Multiple Myeloma	321	3.49	193	4.44	128	2.69
Leukemia	1,080	11.77	628	14.22	452	9.60
Lymphocytic	440	4.72	262	5.72	178	3.79
Acute Lymphocytic	0		171	3.42	115	2.40
Chronic Lymphocytic	150	1.76	88	2.22	62	1.37
Other Lymphocytic	4		3		1	
Myeloid and Monocytic	573	6.30	333	7.75	240	5.08
Acute Myeloid	458	5.00	256	5.79	202	4.28
Acute Monocytic	9		5		4	
Chronic Myeloid	103	1.17	69	1.78	34	0.71
Other Myeloid/Monocytic	3		3		0	
Other	67	0.75	33	0.76	34	0.73
Other Acute	47	0.54	23	0.54	24	0.53
Aleukemic, Subleukemic and NOS	20	0.21	10	0.22	10	0.20
Mesothelioma	0		0		0	
Kaposi Sarcoma	2		1		1	
Other, Ill-Defined and Unspecified Sites	6,438	70.48	2,873	66.86	3,565	75.29

^{*} Those of unknown gender are not shown separately, but are included in the total.

^{**} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Table 12. Top Ten Types of Cancer Inpatient Hospital Discharges by County/Region of Residence, Nevada Residents, 1997-2001

				County/Region	n of Residence	
Rank	Type of Cance	er	Nevada Total	Clark	Washoe	All Other Counties
1	Lung and Bronchus	Admissions	4,965	3,562	748	654
		Rate*	54.28	58.13	49.49	43.60
		95% C.I.	(52.8-55.8)	(56.2-60.1)	(46.0-53.2)	(40.3-47.2)
2	Colorectal	Admissions	4,196	2,928	706	562
		Rate*	48.62	50.70	49.21	39.44
		95% C.I.	(47.1-50.2)	(48.8-52.7)	(45.6-53.1)	(36.2-42.9)
3	Breast*	Admissions	2,589	1,787	459	341
		Rate*	54.69	56.35	56.47	45.57
		95% C.I.	(52.6-56.9)	(53.8-59.1)	(51.4-61.9)	(40.8-50.7)
4	Prostate*	Admissions	2,536	1,679	426	431
		Rate*	56.03	55.84	56.16	56.85
		95% C.I.	(53.8-58.4)	(53.0-58.8)	(50.8-62.2)	(51.4-62.9)
5	Leukemia	Admissions	1,080	807	138	134
		Rate*	11.77	13.04	8.81	9.59
		95% C.I.	(11.1-12.5)	(12.1-14.0)	(7.4-10.5)	(8.0-11.4)
6	Urinary Bladder	Admissions	1,022	728	144	149
		Rate*	11.93	12.85	10.05	10.22
		95% C.I.	(11.2-12.7)	(11.9-13.9)	(8.5-11.9)	(8.6-12.1)
7	Non-Hodgkin's Lymphoma	Admissions	988	673	182	133
		Rate*	11.01	11.18	12.05	9.20
		95% C.I.	(10.3-11.7)	(10.3-12.1)	(10.3-14.0)	(7.7-11.0)
8	Corpus Uteri & Uterus NOS	Admissions	828	582	128	118
	•	Rate*	17.31	18.04	15.81	15.85
		95% C.I.	(16.1-18.5)	(16.6-19.6)	(13.2-18.8)	(13.1-19.0)
9	Kidney and Renal Pelvis	Admissions	905	611	144	150
	·	Rate*	9.70	9.77	9.18	9.95
		95% C.I.	(9.1-10.4)	(9.0-10.6)	(7.7-10.9)	(8.4-11.7)
10	Thyroid Gland	Admissions	985	757	151	
		Rate*	10.06	11.38	8.81	
	95% C.I.		(9.4-10.7)	(10.6-12.2)	(7.5-10.4)	
	Total	Admissions	33,235	23,445	5,453	4,325
		Rate*	364.78	383.60	357.93	293.70
		95% C.I.	(360.8-368.8)	(378.6-388.7)	(348.4-367.7)	(284.9-302.8)

^{*} Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" indicates that this type of cancer was not in the Top Ten for this specific region.

Table 13. Top Ten Types of Cancer Hospital Discharges by Age Group, Nevada Residents, 1997-2001

Abbreviations: Brain and OCNS = Brain and Other Central Nervous System, CU & Uterus NOS = Corpus Uteri and Uterus NOS, HL = Hodgkin's Lymphoma, KRP = Kidney and Renal Pelvis, LOCP = Lip, Oral Cavity and Pharynx, Liver and IBD = Liver and Intrahepatic Bile Ducts, NHL = Non-Hodgkin's Lymphoma. Note: Those cases with unknown ages are not shown separately, but are included in the total.

Ranking					Age Group				
Ranking	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75+	Total
1	Leukemia	Leukemia	Thyroid Gland	Breast	Breast	Lung and Bronchus		Colorectal	Lung and Bronchus
	216	58	179	293	523	1,267	1,870	1,456	9,930
	48.0%	19.9%	22.3%	14.3%	11.7%	16.1%	19.1%	19.4%	14.9%
2	Brain and OCNS	Thyroid Gland	Leukemia	Thyroid Gland	Lung and Bronchus	Prostate	Colorectal	Lung and Bronchus	Colorectal
	68	57	66	268	480	941	1,347	1,211	8,392
	15.1%	19.6%	8.2%	13.0%	10.8%	12.0%	13.7%	16.1%	12.6%
3	KRP	Brain and OCNS	Cervix Uteri	Cervix Uteri	Colorectal	Colorectal	Prostate	Breast	Breast
	24	22	62	179	414	824	963	518	5,216
	5.3%	7.6%	7.7%	8.7%	9.3%	10.5%	9.8%	6.9%	7.8%
4	NHL	NHL		Lung and Bronchus	Prostate	Breast	Breast	Urinary Bladder	Prostate
	18	21	57	124	273	610	610	410	5,072
	4.0%	7.2%	7.1%	6.0%	6.1%	7.8%	6.2%	5.5%	7.6%
5	Liver and IBD	HL	NHL	Colorectal	Thyroid Gland	KRP	Urinary Bladder	Prostate	Leukemia
	15	18	54	121	220	238	338	347	2,160
	3.3%	6.2%	6.7%	5.9%	4.9%	3.0%	3.4%	4.6%	3.2%
6	Thyroid Gland	Cervix Uteri	Breast	Brain and OCNS	Cervix Uteri	CU & Uterus NOS	NHL	NHL	Urinary Bladder
	7	10	51	92	158	199	263	260	2,044
	1.6%	3.4%	6.4%	4.5%	3.5%	2.5%	2.7%	3.5%	3.1%
7	HL	Ovary	Colorectal	Ovary	KRP	Urinary Bladder	KRP	Pancreas	NHL
	6	6	31	66	149	193	262	210	1,976
	1.3%	2.1%	3.9%	3.2%	3.3%	2.5%	2.7%	2.8%	3.0%
8	Breast	Lung and Bronchus	Ovary	KRP	CU & Uterus NOS	NHL	Pancreas	Leukemia	Thyroid Gland
	2	5	29	62	147	188	254	198	1,970
	0.4%	1.7%	3.6%	3.0%	3.3%	2.4%	2.6%	2.6%	3.0%
9	Ovary	Stomach	CU & Uterus NOS	Leukemia	Ovary	LOCP	CU & Uterus NOS	Stomach	KRP
	2	5	22	55	138	181	253	176	1,810
	0.4%	1.7%	2.7%	2.7%	3.1%	2.3%	2.6%	2.3%	2.7%
10	Urinary Bladder	Liver and IBD	HL	CU & Uterus NOS	NHL	Leukemia	Leukemia	KRP	CU & Uterus NOS
	2	4	20	53	135	171	222	161	1,656
	0.4%	1.4%	2.5%	2.6%	3.0%	2.2%	2.3%	2.1%	2.5%
Sum	360	206	571	1,313	2,637	4,812	6,382	4,947	40,226
Percent	80.0%	70.8%	71.1%	63.9%	59.1%	61.3%	65.0%	65.9%	60.5%
Total	450	291	803	2,054	4,463	7,852	9,814	7,508	66,470
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

MORTALITY

HIGHLIGHTS

- ➤ Lung and Bronchus Cancer was the leading type of cancer for cancer mortality in Nevada from 1997 to 2001. This type of cancer accounted for 32.0% of all resident cancer deaths during this period. The second leading type of cancer for mortality was Colorectal Cancer, which accounted for 10.8% of all cancer deaths.
- ▶ Blacks had the highest ratio of the remaining racial/ethnic groups when compared to the age-adjusted cancer mortality rates for Whites with a comparison ratio of 1.08. This means that for every 100 White cancer deaths Blacks would be expected to have 108 deaths. Native Americans, Asians and Hispanics had comparison ratios of 0.54, 0.54 and 0.46, respectively, for Nevada from 1997 to 2001.
- ➤ Stomach Cancer had the highest age-adjusted mortality rate comparison ratio for Blacks when compared to Whites in Nevada from 1997 to 2001 with a ratio of 1.91. This means that for every 100 White Stomach Cancer deaths, Blacks would be expected to have 191 deaths. The type of cancer with the highest comparison ratio for Native Americans was Stomach with a ratio of 1.61, and Asians was Liver and Intrahepatic Bile Ducts with a ratio of 1.87. Stomach also had the highest comparison ratio for Hispanics when compared to Whites with a ratio of 1.33.
- Skin Cancer had the lowest age-adjusted mortality rate comparison ratio for Blacks and Asians when compared to Whites in Nevada from 1997 to 2001 with ratios of 0.15 and 0.11. This means that for every 100 White cancer cases Blacks and Asians would be expected to have 15 and 11 deaths, respectively, from Skin Cancer. The type of cancer with the lowest age-adjusted mortality rate comparison ratio for Native Americans was Urinary Bladder Cancer with a ratio of 0.14 during this period. The type of cancer with the lowest age-adjusted mortality rate comparison ratio for Hispanics was Larynx Cancer with a ratio of 0.08.
- ➤ Cervical Cancer had the lowest median age at time of death for Nevada residents from 1997 to 2001 at 55 years. Prostate Cancer had the highest median age at time of death for Nevada residents at 77 years.
- ➤ Hodgkin's Lymphoma had the lowest median age at time of death for male Nevada residents from 1997 to 2001 at 55 years, while the highest median age at time of death for males in Nevada was Prostate Cancer at 76 years.
- ➤ Cervical Cancer had the lowest median age at time of death for Female Nevada Residents during this same period at 53 years, while the highest median age for females in Nevada was for Stomach and Urinary Bladder Cancer at 75 years.

Figure 15. Top Ten Leading Cancers by Percentage of Total Cancer Mortality, Nevada Residents, 1997-2001




Figure 16. Comparison of Age-Adjusted (2001) Mortality Rates of Blacks compared to Whites, Nevada Residents, 1997-2001






Figure 17. Comparison of Age-Adjusted (2001) Mortality Rates of Native Americans compared to Whites, Nevada Residents, 1997-2001



Note: "N/A" indicates that a comparison ratio could not be calculated.

Figure 18. Comparison of Age-Adjusted (2001) Mortality Rates of Asians compared to Whites, Nevada Residents, 1997-2001



Note: "N/A" indicates that a comparison ratio could not be calculated.

Figure 19. Comparison of Age-Adjusted (2001) Mortality Rates of Hispanics compared to Whites, Nevada Residents, 1997-2001




Table 14. Nevada Mortality by Type of Cancer and Gender, Nevada, 1997-2001

pe of Cancer	Total*		Male		Female	
	Number	Rate**	Number	Rate**	Number	Rate**
Total	17,459	204.62	9,476	242.86	7,983	175.83
Lip, Oral Cavity and Pharynx	225	2.53	142	3.24	83	1.84
Lip	1		0		1	
Base of Tongue	3		2		1	
Other & Unspecified Parts of Tongue	60	0.64	39	0.86	21	0.44
Parotid Gland	13	0.15	6		7	
Other & Unspecified Major Salivary glands	3		3		0	
Floor of Mouth	4		2		2	
Gum	3		1		2	
Palate	4		3		1	
Other & Unspecified Parts of Mouth	25	0.29	14	0.30	11	0.26
Nasopharynx	24	0.26	16	0.34	8	
Tonsil	15	0.16	10	0.21	5	
Oropharynx	8		5		3	
Pyriform Sinus	0		0		0	
Hypopharynx	3		3		0	
Other & Unspecified Oral (Buccal) Cavity & Pharynx	59	0.68	38	0.93	21	0.46
Digestive System	4,003	47.36	2,307	57.97	1,696	38.11
Esophagus	384	4.23	294	6.72	90	1.96
Stomach	325	3.94	201	5.15	124	2.86
Small Intestine	28	0.32	13	0.33	15	0.33
Colon (excluding Rectum)	1,603	19.53	888	23.16	715	16.38
Cecum	6		3		3	
Appendix	2		2		0	
Ascending Colon	3		1		2	
Hepatic Flexure	0		0		0	
Transverse Colon	1		0		1	
Splenic Flexure	0		0		0	
Descending Colon	0		0		0	
Sigmoid Colon	11	0.12	6		5	
Large Intestine, NOS	1,580	19.23	876	22.83	704	16.12
Rectum	200	2.31	119	2.99	81	1.77
Rectosigmoid Junction	64	0.77	35	0.83	29	0.68
Anus, Anal Canal and Anorectum	24	0.27	13	0.31	11	0.24
Liver	351	4.03	233	5.58	118	2.63
Intrahepatic Bile Ducts	64	0.74	39	0.95	25	0.55
Gallbladder	43	0.53	12	0.41	31	0.68
Other & Unspecified Biliary Tract	34	0.42	22	0.60	12	0.27
Pancreas	845	9.82	419	10.48	426	9.35
Retroperitoneum	6		4		2	
Peritoneum, Omentum and Mesentery	7		1		6	
Other Digestive Organs	25	0.31	14	0.36	11	0.25
Respiratory System	5,729	65.24	3,234	79.46	2,495	53.90
Nasal Cavity and Middle Ear	0		0		0	
Accessory Sinuses	11	0.12	8		3	
Larynx	124	1.41	93	2.22	31	0.68
Lung and Bronchus	5,582	63.56	3,125	76.78	2,457	53.07
Pleura	4		3		1	
Trachea	1		0		1	
Mediastinum and Other Respiratory Organs	7		5	0.50	2	
Bones, Joints and Articular Cartilage	37	0.44	20	0.52	17	0.38
Bones, Joints & Articular Cartilage of Limbs	1		0		1	
Bones, Joints & Articular Cartilage of Other & Unspec Sites	36	0.43	20	0.52	16	0.36
Soft Tissue (Including Heart)	121	1.34	73	1.70	48	1.02
Heart	8		4		4	
Peripheral Nerves & Autonomic Nervous System	3	4 00	2		1	
Connective, Subcutaneous & Other Soft Tissues	110	1.23	67	1.57	43	0.92

^{*} Those of unknown gender are not shown separately, but are included in the total.

^{**}Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Table 14. Nevada Mortality by Type of Cancer and Gender, Nevada, 1997-2001 (Continued)

	Tota	*	Mal	е	Fema	ale
Type of Cancer	Number	Rate**	Number	Rate**	Number	Rate**
Total	17,459	204.62	9,476	242.86	7,983	175.83
Skin (Excluding Basal And Squamous)	345	3.89	242	5.86	103	2.23
Melanomas Of The Skin	264	2.92	181	4.29	83	1.76
Other Non-Epithelial Skin	81	0.98	61	1.57	20	0.47
Breast	1,195	14.02	13	0.34	1,182	25.90
Female Genital System	690	7.99	0		690	15.03
Cervix Uteri	140	1.54	0		140	2.99
Corpus Uteri	59	0.70	0		59	1.30
Uterus, NOS	75	0.93	0		75	1.70
Ovary	376	4.33	0		376	8.16
Vagina	12	0.13	0		12	0.25
Vulva	15	0.20	0		15	0.35
Placenta	1		0		1	
Other Female Genital Organs	12	0.14	0		12	0.26
Male Genital System	943	12.36	943	29.68	0	
Prostate	922	12.14	922	29.21	0	
Testis	17	0.17	17	0.34	0	
Penis	4		4		0	
Other Male Genital Organs	0		0		0	
Urinary System	748	9.06	525	14.03	223	5.10
Urinary Bladder	401	5.09	288	8.29	113	2.67
Kidney	322	3.69	224	5.43	98	2.18
Renal Pelvis	5		2		3	
Ureter	12	0.14	5		7	
Other Urinary Organs	8		6		2	
Eye and Orbit	6		5		1	
Brain and Other Central Nervous System	338	3.71	205	4.60	133	2.86
Brain	335	3.68	204	4.58	131	2.82
Meninges	0		0		0	
Spinal Cord, Cranial Nerves, & Other Parts of CNS	3		1		2	
Endocrine System	53	0.61	28	0.72	25	0.54
Thyroid Gland	29	0.35	16	0.42	13	0.29
Adrenal Gland	15	0.17	7		8	
Other Endocrine (Including Thymus)	9		5		4	
Hodgkin's Lymphoma	38	0.40	22	0.46	16	0.34
Non-Hodgkin's Lymphoma	599	7.08	356	9.40	243	5.34
Multiple Myeloma	261	3.02	155	3.93	106	2.31
Leukemia	614	7.39	368	9.53	246	5.58
Lymphocytic	164	2.06	99	2.78	65	1.51
Acute Lymphocytic	32	0.34	19	0.44	13	0.27
Chronic Lymphocytic	120	1.55	72	2.10	48	1.14
Other Lymphocytic	12	0.17	8		4	
Myeloid and Monocytic	249	2.89	144	3.55	105	2.33
Acute Myeloid	180	2.07	100	2.42	80	1.77
Acute Monocytic	0		0		0	
Chronic Myeloid	53	0.63	31	0.78	22	0.50
Other Myeloid/Monocytic	16	0.19	13	0.36	3	
Other	201	2.43	125	3.20	76	1.74
Other Acute	88	1.02	59	1.46	29	0.64
Aleukemic, Subleukemic and NOS	113	1.41	66	1.73	47	1.10
Mesothelioma	46	0.56	35	1.03	11	0.23
Kaposi Sarcoma	0		0		0	
Other, III-Defined and Unspecified Sites	1,468	17.57	803	20.29	665	15.09
Tanana, and		17.07		20.20		10.00

^{*} Those of unknown gender are not shown separately, but are included in the total.

^{**}Rates are per 100,000 population and age-adjusted to the 2000 US Standard population.

Table 15. Top Ten Types of Cancer Mortality by County/Region of Residence, Nevada Residents, 1997-2001

				County/Region	n of Residence	
Rank	Type of Cancer		Nevada Total	Clark	Washoe	All Other Counties
1	Lung and Bronchus	Mortality	5,582	3,823	911	848
		Rate*	63.56	65.57	62.16	57.64
·		95% C.I.	(61.9-65.3)	(63.4-67.8)	(58.1-66.4)	(53.8-61.8)
2	Colorectal	Mortality	1,891	1,291	328	272
		Rate*	22.88	23.49	23.31	19.99
-		95% C.I.	(21.8-24.0)	(22.2-24.9)	(20.8-26.1)	(17.6-22.6)
3	Breast*	Mortality	1,182	775	235	172
		Rate*	25.90	25.49	29.74	23.52
		95% C.I.	(24.4-27.4)	(23.7-27.4)	(26.0-33.8)	(20.1-27.4)
4	Prostate*	Mortality	922	606	170	146
		Rate*	29.21	28.41	33.68	27.02
		95% C.I.	(27.2-31.4)	(25.9-31.1)	(28.5-39.7)	(22.5-32.3)
5	Pancreas	Mortality	845	572	127	146
		Rate*	9.82	9.93	8.95	10.20
		95% C.I.	(9.1-10.5)	(9.1-10.8)	(7.4-10.7)	(8.6-12.1)
6	Non-Hodgkin's Lymphoma	Mortality	599	398	108	93
		Rate*	7.08	7.12	7.45	6.61
		95% C.I.	(6.5-7.7)	(6.4-7.9)	(6.1-9.1)	(5.3-8.2)
7	Leukemia	Mortality	614	419	104	91
		Rate*	7.39	7.61	7.16	6.85
		95% C.I.	(6.8-8.0)	(6.9-8.4)	(5.8-8.7)	(5.5-8.5)
8	Liver and Intrahepatic Bile Ducts	Mortality	415	299		57
		Rate*	4.77	5.21		4.02
		95% C.I.	(4.3-5.3)	(4.6-5.9)		(3.0-5.3)
9	Urinary Bladder	Mortality	401	272	62	67
		Rate*	5.09	5.33	4.48	4.91
		95% C.I.	(4.6-5.6)	(4.7-6.1)	(3.4-5.8)	(3.8-6.3)
10	Esophagus	Mortality	384	268	68	
		Rate*	4.23	4.45	4.48	
		95% C.I.	(3.8-4.7)	(3.9-5.0)	(3.5-5.7)	
	Total	Mortality	17,459	11,761	3,005	2,693
		Rate*	204.62	207.06	209.37	190.61
		95% C.I.	(201.5-207.8)	(203.2-211.0)	(201.8-217.2)	(183.3-198.1)

 $[\]ast$ Rates are per 100,000 population and age-adjusted to the 2000 US Standard population. Gender specific cancers are per 100,000 gender-specific population and age-adjusted to the 2000 US Standard population.

Note: The "---" indicates that this type of cancer was not in the Top Ten for this specific region.

Table 16. Top Ten Types of Cancer Mortality by Age Group, Nevada Residents, 1997-2001

Abbreviations: Brain and OCNS = Brain and Other Central Nervous System, CU & Uterus NOS = Corpus Uteri and Uterus NOS, HL = Hodgkin's Lymphoma, KRP = Kidney and Renal Pelvis, LOCP = Lip, Oral Cavity and Pharynx, Liver and IBD = Liver and Intrahepatic Bile Ducts, NHL = Non-Hodgkin's Lymphoma.

Ranking					Age Group				
Natikitig	0-14	15-24	25-34	35-44	45-54	55-64	65-74	75+	Total
1	Leukemia	Leukemia	Brain and OCNS	Breast	Lung and Bronchus	Lung and Bronchus	Lung and Bronchus	Lung and Bronchus	Lung and Bronchi
	16	13	15	92	428	1,173	2,063	1,836	5,582
	32.7%	32.5%	13.6%	18.5%	27.7%	35.1%	37.4%	28.9%	32.0%
2	Brain and OCNS	NHL	Leukemia	Lung and Bronchus	Breast	Colorectal	Colorectal	Colorectal	Colorectal
	12	4	10	75	195	320	598	783	1,891
	24.5%	10.0%	9.1%	15.1%	12.6%	9.6%	10.8%	12.3%	10.8%
3	Liver and IBD	Brain and OCNS	NHL	Colorectal	Colorectal	Breast	Pancreas	Prostate	Breast
	3	3	10	52	128	250	281	569	1,195
	6.1%	7.5%	9.1%	10.4%	8.3%	7.5%	5.1%	8.9%	6.8%
4	KRP	Liver and IBD	Colorectal	Brain and OCNS	Pancreas	Pancreas	Prostate	Breast	Prostate
	1	3	9	29	77	169	275	380	922
	2.0%	7.5%	8.2%	5.8%	5.0%	5.1%	5.0%	6.0%	5.3%
5		Skin	Breast	Skin	Liver and IBD	Esophagus	Breast	Pancreas	Pancreas
		3	6	28	62	123	271	302	845
		7.5%	5.5%	5.6%	4.0%	3.7%	4.9%	4.7%	4.8%
6		HL	Cervix Uteri	Cervix Uteri	Ovary	NHL	NHL	Leukemia	Leukemia
		2	6	24	62	97	174	254	614
		5.0%	5.5%	4.8%	4.0%	2.9%	3.2%	4.0%	3.5%
7		Breast	Skin	Leukemia	NHL	Leukemia	Leukemia	NHL	NHL
		1	6	23	54	91	155	239	599
		2.5%	5.5%	4.6%	3.5%	2.7%	2.8%	3.8%	3.4%
8		Colorectal	HL	NHL	Leukemia	KRP	Liver and IBD	Urinary Bladder	Liver and IBD
		1	4	20	52	80	132	208	415
		2.5%	3.6%	4.0%	3.4%	2.4%	2.4%	3.3%	2.4%
9		LOCP	Lung and Bronchus	Ovary	Brain and OCNS	Liver and IBD	Esophagus	Stomach	Urinary Bladder
		1	4	15	43	77	118	141	401
		2.5%	3.6%	3.0%	2.8%	2.3%	2.1%	2.2%	2.3%
10		Pancreas & Skin	Pancreas	Stomach	Skin	Brain and OCNS	Ovary	Liver and IBD	Esophagus
		1 (each)	4	13	41	74	114	126	384
		2.5%	3.6%	2.6%	2.7%	2.2%	2.1%	2.0%	2.2%
Sum	32	31	74	371	1,142	2,454	4,181	4,838	12,848
Percent	65.3%	77.5%	67.3%	74.5%	74.0%	73.4%	75.9%	76.1%	73.6%
Total	49	40	110	498	1,543	3,345	5,512	6,360	17,459
	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Note: Those cases with unknown ages are not shown separately, but are included in the total.

Table 17. Median Age at Time of Death by Leading Types of Cancer and Race/Ethnicity, Nevada Residents, 1997-2001

	Race/Ethnicity											
Type of Cancer	White		Black		Native American		Asian		Hispanic		Total	
	Number	Age	Number	Age	Number	Age	Number	Age	Number	Age	Number	Age
Lung and Bronchus	5,090	70.0	276	67.0	26	68.5	95	67.0	89	66.0	5,580	70.0
Breast	1,037	68.0	77	62.0	5	59.0	27	55.0	49	55.0	1,195	67.0
Prostate	810	77.0	69	75.0	4		13	74.0	26	74.5	922	77.0
Colorectal	1,650	72.0	120	67.0	13	68.0	45	66.0	62	69.0	1,891	72.0
Urinary Bladder	376	75.0	11	77.0	1		5	79.0	8	78.5	401	75.0
Non-Hodgkin's Lymphoma	535	72.0	17	66.0	3		20	72.0	24	69.0	599	72.0
Kidney and Renal Pelvis	284	71.0	13	72.0	2		7	61.0	19	65.0	327	71.0
Leukemia	539	73.0	26	65.0	3		12	63.5	32	62.5	614	72.0
Lip, Oral Cavity and Pharynx	201	67.0	13	64.0	1		3		7	72.0	225	67.0
Pancreas	726	71.0	50	68.0	7	68.0	17	68.0	42	68.0	845	70.0
Skin	257	64.0	2		1		2		2		264	64.0
Corpus Uteri & Uterus NOS	114	70.5	11	70.0	1		4		4		134	70.5
Ovary	332	70.0	20	65.5	2		7	59.0	15	61.0	376	69.0
Thyroid Gland	25	73.0	1		0		1		2		29	73.0
Stomach	246	74.0	25	68.0	4		20	63.0	30	62.5	325	73.0
Brain and Other Central Nervous System	295	64.0	13	66.0	1		11	58.0	18	47.5	338	63.5
Cervix Uteri	107	55.0	8	54.0	1		11	60.0	12	56.0	140	55.0
Liver and Intrahepatic Bile Ducts	323	71.0	26	55.0	5	67.0	33	58.0	27	60.0	415	69.0
Esophagus	337	68.0	28	62.0	0		8	62.5	11	61.0	384	67.5
Larynx	112	68.0	8	68.0	1		2		1		124	68.0
Multiple Myeloma	217	72.0	24	62.5	2		6	61.5	11	71.0	261	71.0
Hodgkin's Lymphoma	34	61.5	2		0		0		2		38	61.5
All Other Sites	1,799	71.0	96	65.0	17	71.0	36	66.0	80	62.5	2,030	71.0
Total	15,446	71.0	936	67.0	100	68.0	385	65.0	573	65.0	17,457	71.0

Note: Those of other/unknown race/ethnicity are not shown separately, but are included in the total. Those deaths of other/unknown gender and/or unknown ages are not included in this table. The median age was not calculated for those numbers less than five.

SURVIVAL RATE

HIGHLIGHTS

- ➤ Thyroid Gland Cancer had the highest one-year survival rate of all types of cancer in Nevada from 1997 to 2001 with a rate of 97.3%. This was followed by Breast, Uterine, Prostate, and Skin Cancers, which had one-year survival rates of 95.2%, 94.7%, 94.4%, and 91.6%, respectively.
- ➤ Pancreatic Cancer had the lowest one-year survival rate of all types of cancer in Nevada from 1997 to 2001 with a rate of 34.0%. This was followed by Liver and Intrahepatic Bile Ducts, Stomach, Lung and Bronchus, and Esophagus Cancer, which had One-Year Survival rates of 35.3%, 44.6%, 46.4%, and 48.6%, respectively.
- ➤ The five types of cancer with the highest five-year survival rates in Nevada from 1997 to 2001 were Thyroid Gland (96.1%), Breast (83.2%), Hodgkin's Lymphoma (81.7%), Prostate (80.4%), and Corpus Uteri & Uterus NOS (77.2%) Cancers.
- ➤ The five types of cancer with the lowest five-year survival rates in Nevada from 1997 to 2001 were Liver and Intrahepatic Bile Ducts (10.2%), Pancreatic (11.2%), Stomach (20.5%), Esophagus (21.5%), and Lung and Bronchus (22.1%) Cancers.

Figure 20. Ten Highest One-Year Survival Rates by Type of Cancer, Nevada Residents, 1997-2001




Figure 21. Ten Lowest One-Year Survival Rates by Type of Cancer, Nevada Residents, 1997-2001




Figure 22. Ten Highest Five-Year Survival Rates by Type of Cancer, Nevada Residents, 1997-2001




Figure 23. Ten Lowest Five-Year Survival Rates by Type of Cancer, Nevada Residents, 1997-2001




Table 18. One-Year, Five-Year and Median Survival Rates by Type of Cancer, Nevada Residents, 1997-2001

Type of Cancer	1-Year	5-Year	Median Survival (Years)	
Lung and Bronchus	46.4%	22.1%	0.93	
Colorectal	77.5%	53.2%	>5 years	
Breast	95.2%	83.2%	>5 years	
Prostate	94.4%	80.4%	>5 years	
Pancreas	34.0%	11.2%	0.76	
Non-Hodgkin's Lymphoma	74.9%	57.3%	>5 years	
Leukemia	62.5%	46.7%	3.31	
Liver and Intrahepatic Bile Ducts	35.3%	10.2%	0.77	
Urinary Bladder	87.3%	74.9%	>5 years	
Esophagus	48.6%	21.5%	0.97	
Ovary	76.8%	51.9%	>5 years	
Stomach	44.6%	20.5%	0.90	
Kidney and Renal Pelvis	76.7%	64.0%	>5 years	
Brain and Other Central Nervous System	57.1%	40.7%	1.64	
Skin	91.6%	71.4%	>5 years	
Multiple Myeloma	73.8%	48.8%	3.76	
Lip, Oral Cavity and Pharynx	82.2%	55.0%	>5 years	
Larynx	78.1%	58.3%	>5 years	
Cervix Uteri	86.2%	74.6%	>5 years	
Corpus Uteri & Uterus NOS	94.7%	77.2%	>5 years	
Hodgkin's Lymphoma	91.0%	81.7%	>5 years	
Thyroid Gland	97.3%	96.1%	>5 years	
All Other Sites	67.1%	48.4%	3.37	
Total	73.5%	54.7%	>5 years	

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 19. One- and Five-Year Survival Rates by Type of Cancer and Gender, Nevada Residents, 1997-2001

	Gender								
Type of Cancer	Tot	al	Ma	ale	Female				
	1-Year	5-Year	1-Year	5-Year	1-Year	5-Year			
Lung and Bronchus	46.4%	22.1%	44.1%	21.3%	49.3%	23.1%			
Colorectal	77.5%	53.2%	76.2%	52.9%	78.8%	53.6%			
Breast	95.2%	83.2%			95.1%	83.1%			
Prostate	94.4%	80.4%	94.4%	80.4%					
Pancreas	34.0%	11.2%	35.5%	14.5%	32.4%	9.1%			
Non-Hodgkin's Lymphoma	74.9%	57.3%	74.6%	62.5%	75.3%	50.5%			
Leukemia	62.5%	46.7%	61.7%	49.1%	63.7%	43.5%			
Liver and Intrahepatic Bile Ducts	35.3%	10.2%	35.3%		35.2%	16.0%			
Urinary Bladder	87.3%	74.9%	88.2%	76.7%	84.6%	69.3%			
Esophagus	48.6%	21.5%	48.8%	21.8%	47.9%				
Ovary	76.8%	51.9%			76.8%	51.9%			
Stomach	44.6%	20.5%	45.3%	22.3%	43.2%	18.0%			
Kidney and Renal Pelvis	76.7%	64.0%	76.0%	64.4%	78.0%	63.4%			
Brain and Other Central	57.4 0/	40.70/	EE 00/	0.4.007	50.7 0/	40.00/			
Nervous System	57.1%	40.7%	55.9%	34.0%	58.7%	48.2%			
Skin	91.6%	71.4%	89.5%	67.1%	94.8%	78.2%			
Multiple Myeloma	73.8%	48.8%	70.0%	45.0%	79.8%	54.4%			
Lip, Oral Cavity and Pharynx	82.2%	55.0%	82.2%	52.9%	82.0%	61.3%			
Larynx	78.1%	58.3%	78.5%	56.8%	76.5%	62.6%			
Cervix Uteri	86.2%	74.6%			86.2%	74.6%			
Corpus Uteri & Uterus NOS	94.7%	77.2%			94.7%	77.2%			
Hodgkin's Lymphoma	91.0%	81.7%	87.8%	79.6%	94.7%	83.9%			
Thyroid Gland	97.3%	96.1%	93.1%	88.0%	98.4%	98.4%			
All Other Sites	67.1%	48.4%	69.9%	54.3%	62.9%	40.3%			
Total	73.5%	54.7%	70.6%	51.4%	76.4%	58.0%			

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.

Table 20. One- and Five-Year Survival Rates by Type of Cancer and Race/Ethnicity, Nevada Residents, 1997-2001

Type of Cancer		Race/Ethnicity							
		Total	White	Black	Native American	Asian	Hispanic		
Lung and Bronchus	1-Year	46.4%	45.7%	48.3%		53.8%	53.4%		
	5-Year	22.1%	21.4%	23.0%		23.0%	36.8%		
Colorectal	1-Year 5-Year	77.5% 53.2%	76.9% 52.4%	78.6% <u>51.2%</u>		80.0% 66.4%	81.9% 56.8%		
Breast	1-Year 5-Year	95.2% 83.2%	95.3% 83.2%	88.5% 76.8%		96.9% 90.6%	95.1% 71.5%		
Prostate	1-Year	94.4%	94.0%	95.6%		30.076	100.0%		
Trodicto	5-Year	80.4%	79.5%	75.3%					
Pancreas	1-Year	34.0%	32.9%						
Tarlorcas	5-Year	11.2%	9.8%						
Non-Hodgkin's Lymphoma	1-Year 5-Year	74.9% 57.3%	74.5% 56.5%						
Leukemia	1-Year	62.5%	60.2%				73.2%		
Leukeiilla	5-Year	46.7%	45.0%				45.4%		
Liver and Intrahepatic Bile	1-Year	35.3%	34.1%						
Ducts	5-Year	10.2%	10.4%						
Urinary Bladder	1-Year	87.3%	87.1%						
	5-Year	74.9%	75.4%						
Esophagus	1-Year	48.6%	46.9%						
	5-Year	21.5%	20.7%						
Ovary	1-Year 5-Year	76.8% 51.9%	76.5% 50.6%						
Stomach	1-Year	44.6%	44.8%						
Stomach	5-Year	20.5%	19.4%						
Kidney and Renal Pelvis	1-Year	76.7%	75.6%						
radioy and renair one	5-Year	64.0%	61.5%						
Brain and Other Central	1-Year	57.1%	55.6%						
Nervous System	5-Year	40.7%	37.1%						
Skin	1-Year	91.6%	91.3%						
	5-Year	71.4%	71.0%						
Multiple Myeloma	1-Year	73.8%	72.8%						
	5-Year	48.8%	43.7%						
Lip, Oral Cavity and Pharynx		82.2%	82.0%						
Lance	5-Year	55.0%	54.2%						
Larynx	1-Year	78.1%	77.9%						
Cervix Uteri	5-Year 1-Year	<u>58.3%</u> 86.2%	<u>56.1%</u> 83.4%						
Cervix Oteri	5-Year	74.6%	74.8%						
Corpus Uteri & Uterus NOS	1-Year	94.7%	95.0%						
Corpus Oteria Oteras 1400	5-Year	77.2%	78.6%						
Hodgkin's Lymphoma	1-Year	91.0%	91.8%						
	5-Year	81.7%	81.0%						
Thyroid Gland	1-Year	97.3%	97.2%						
	5-Year	96.1%	95.8%						
All Other Sites	1-Year	67.1%	66.5%	60.9%			71.2%		
	5-Year	48.4%	48.9%	28.1%			47.3%		
Total	1-Year 5-Year	73.5% 54.7%	72.9% 53.9%	71.2% 47.7%	59.0% 46.5%	75.4% 63.2%	78.4% 62.0%		

Notes: 1) The "---" indicates that survival rate could not be calculated due to small cell size. Caution should be used when interpreting survival rates based upon categories with a small number of cases. 2) Those cases where the gender and/or race/ethnicity were other/unknown, are not shown separately, but are included in the category totals. 3) These rates may not be directly comparable to National rates because of different methodologies. Caution should be used when trying to compare rates for Nevada and the Nation. For more information on the calculation of survival rates, please refer to Technical Notes section.